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ABSTRACT
Macrocycles (MCs) have become an increasing area of interest for drug design
efforts, especially for classically “difficult” targets like protein-protein interactions
(PPIs). And although there are many examples of successful MC drugs derived from
natural products, there is little information about the characteristics of compounds
with effective pharmacological and physicochemical properties. In this dissertation,
I describe the development of design guidelines for new MC drugs based on a rep-
resentative set of known inhibitor MCs and their target proteins. Analysis of both
the individual MC structures and their interactions in the protein complex resulted
in identification of several structural and physicochemical features likely to promote
favorable binding and bioavailability. Additionally, investigation of the binding sites
on the proteins suggest that MCs can bind targets conventionally considered “non-
druggable,” strengthening the argument for exploring MC compounds to increase the
druggable target space. Furthermore, this work includes the application of the pro-
posed design guidelines to the development of synthetic MC libraries for a PPI target,
the NEMO/IKKβ complex.
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1Chapter 1
Introduction and Background
In the modern era of drug discovery, protein target selection has become increasingly
more important, and more complicated. “Difficult” drug targets, once shied away
from or overlooked for more readily druggable candidates, have renewed appeal for
drug design efforts. Because of this shift in interest it is recognized that the “tra-
ditional” chemical space of conventional druglike compounds is likely insufficient to
address many of these new targets. The move towards acceptance and inclusion of
fragment based approaches is one way that the drug discovery process has attempted
to increase the chemical space being explored. Another increasingly favored way to
improve the use of chemical space is exploration outside the long held parameters of
what an “ideal” drug should look like.
1.1 Macrocycle Compound Class
The general term “macrocycle” (MC) is used to describe a broad range of compounds
and the definition can vary depending on field of study. The most common criterion
to qualify a compound as a macrocycle tends to be: a compound that contains a
contiguous ring of around 12 or more covalently connected atoms (Driggers et al.,
2008; Wessjohann et al., 2005). This definition includes molecules of many shapes
and sizes with widely varying functions, from 12 atom single-ring metal chelating
compounds to large cyclic sugars and vitamins such as B12 with MW greater than
1000. The variation in both size and chemical composition and structure is clearly
illustrated in just the few examples shown in Figure 1·1. In medicinal chemistry the
2term macrocycle has come to refer to organic compounds resembling classic MC drugs
derived from natural products. These compounds typically comprise only C, O, N,
S, and Cl atom types and contain functional groups common to conventional drugs,
or have a structure similar to cyclized peptides. Herein macrocycles will be discussed
in terms of this medicinal chemistry perspective.
Figure 1·1: Example of some naturally occurring macrocycle structures.
1.1.1 The Shift Away from MCs in Drug Discovery
Macrocyclic compounds have been used successfully in disease therapy for over half a
century, with applications as antibiotics, antifungals, immunosuppressants, antipara-
sitics, and cancer therapies. However, unlike typical small-molecule drugs, MC drugs
are almost all closely based on, or identical to, macrocycles occurring in nature (Drig-
gers et al., 2008). Immunosuppressants such as FK506 (tacrolimus) and rapamycin,
isolated from bacteria (Kino et al., 1987; Vezina et al., 1975), and cyclosporine A
(CsA), isolated from a fungus (Borel et al., 1976), are examples of biological MCs
that were developed into drugs and achieved great commercial success. Despite these
favorable outcomes (and many others) early on, the pharmaceutical industry became
cautious about macrocyclic compounds and, until recently, largely avoided discovery
campaigns based on them.
3The institutional bias against macrocycles that crept into drug discovery and
became self-propagating was a result of a few important changes in the lead de-
velopment process in the pharmaceutical industry. First, the synthetic difficulties
associated with macrocycles were a deterrent for medicinal chemists both technically
and financially. The potential for oligomerization of linear precursors to occur in
competition with ring closing, especially in smaller, more strained ring sizes, requires
high dilution and long reaction times. Combining this with the low yields and long
reaction sequences associated with classical total synthesis of MCs, even the numer-
ous successful MC drugs could not allay concerns of delays to development time and
increased costs (Marsault and Peterson, 2011; Wessjohann and Ruijter, 2005; Bog-
dan et al., 2012). The discouragement arising from these initial synthesis aspects was
compounded by the fact that the same difficulties would limit the scope for medicinal
chemistry optimization of a promising lead found through this problematic chemistry.
Furthermore, the extremely low number of compounds that could be produced by a
given team of chemists meant that sufficiently large and diverse screening libraries
couldn’t be created. Meaning MCs would likely only be considered for particular tar-
gets where known acyclic compounds or specific pharmacophores could be used as a
design guide. Therefore MCs long suffered from a lack of reliable and robust synthetic
methods allowing for large library production, and easy exploration of derivatives in
the optimization process.
The second shift away from MCs came with the development of “Lipinski’s Rules”
or the “Rule of 5” (RO5) in 1997 (Lipinski et al., 1997). The RO5 put MCs, and
other complex natural products (even commercially successful ones), into a difficult
category in the drug discovery world because they often violate multiple criteria of
now-accepted success guidelines. Once the RO5 became widely accepted and screen-
ing libraries came to routinely apply them as filtering criteria, bias arose in lead
4development. Screening now tended to preclude the large, often more hydrogen bond
donor/acceptor rich MCs. Additionally, there was a decrease in the use of natural
products for drug discovery overall (Butler, 2005), and because the majority of MC
drugs and leads had been natural product-based, it follows that MC compounds as
new drug leads would decline as well. The combination of these factors kept interest
in MC compounds relatively low even though it was known they can be successful
drugs.
1.1.2 New Understanding and Renewed Interest in MC Drugs
For many years, the number of new drugs brought to market had steadily declined,
even as R&D spending had grown (Scannell et al., 2012; Bunnage, 2011). Conse-
quently, the pharmaceutical industry was prompted to look for new innovation and
growth strategies, both in terms of new drug targets and discovery approaches. His-
torically, biomedical research has focused on only a few targets, relative to the num-
ber of proteins estimated as relevant to disease. Only small subsets of even highly
targeted protein families are the focus of research efforts, and many new leads are de-
signed against well known targets (Bunnage, 2011; Hopkins and Groom, 2002). One
response to the need for improved target selection has been attention to so-called “un-
druggable” targets, such as protein-protein interactions (PPI). These types of targets
had previously been avoided due to the difficulty in identifying small molecule drug
leads that bind at their large, often shallow binding sites (Arkin and Wells, 2004).
This increased pursuit of targets that have traditionally been considered intractable
has renewed interest in non-canonical drug chemotypes, such as macrocycle drugs.
MC compounds are of particular interest because of the long demonstrated ability
of successful natural product (and natural product derived) MC drugs to modulate
such undruggable proteins, including PPI interface sites (Van Duyne et al., 1993; Liu
et al., 1991; Butler, 2005; Driggers et al., 2008; Ganesan, 2008).
5The interest in MC lead compounds has partly been driven by the growing agree-
ment that the Ro5 may be overemphasized in the modern drug discovery process.
Researchers suggest that strict adherence to its parameters detrimentally limits the
chemical space explored, likely resulting in missed opportunities (Doak et al., 2014;
Zhang and Wilkinson, 2007; Abad-Zapatero, 2007). Indeed, many very successful
natural product based drugs would have been excluded from drug discovery schemes
if they had been subject to Ro5 cutoffs (Ganesan, 2008). It has been shown that
compounds with MW over 500 can still be druglike and exhibit good bioavailability,
with factors such as lipophilicity and flexibility (no. of rotatable bonds) being more
important for oral bioavailability (Veber et al., 2002; Vistoli et al., 2008). As the phar-
maceutical industry opens the door to “beyond Ro5” molecules for lead compounds,
MCs are being re-included in the chemical space considered for lead investigation.
Advancements in MC Synthesis
Concurrent with the growing interest in MCs, advancements in synthetic methodology
have made the preparation and study of this previously underused compound class
more viable and widely attractive. Interest in the total synthesis of important natu-
ral products drove the development of reliable and versatile cyclization methods, and
helped reverse attitudes towards MCs as a potential source of medicinal compounds.
Traditional methods of lactonization—and to a lesser extent, lactamization—have
been well explored (Parenty et al., 2013) as methods for cyclization, and they remain
prevalent due to the frequency of these moieties in natural product MCs. These ap-
proaches benefit from the ability to create a variety of ring size and diverse products,
and there are now multiple established and reliable methodologies for such synthesis
(Wessjohann and Ruijter, 2005; Yu and Sun, 2013). The development of “click chem-
istry” and its widespread applications and popularity in organic synthesis (Kolb and
Sharpless, 2003) have also spurred numerous cyclization efforts (Pasini, 2013). One
6extremely important cyclization method, which experienced tremendous development
and became quite widespread, is ring-closing metathesis (RCM) (de Weghe and Eu-
stache, 2005), a high yielding and versatile method that is useful for various ring
sizes. RCM also benefits from the potential for further functionalization though the
double bond that is created in the ring closure process (Mallinson and Collins, 2012),
which can be difficult or limited in some of the other approaches. These are only a
few of the most common and well established methodologies for accessing synthetic
MCs; comprehensive reviews by Marsault & Peterson and others provide a thorough
discussion of synthesis techniques for MCs, as well as describing a number of specific
examples (Marsault and Peterson, 2011; Wessjohann and Ruijter, 2005; Yu and Sun,
2013).
Although the synthetic methods outlined above have produced promising and
important compounds, many of them still have limitations that make them unfavor-
able for widespread integration into drug discovery programs. Chief among these
limitations are: (1) dilution requirements to avoid oligomerization over the desired
ring-closed product—with the large reaction volumes required often overlooked in
favor of features like yield (Collins and James, 2012), and (2) low throughput in com-
pound synthesis, resulting from long reaction times and multistep processes, which
limits access to screening libraries of useful size. One strategy developed to im-
prove reaction conditions and allow for easy diversification is the use of solid phase
techniques, in which some of the advances in cyclization chemistry from total syn-
thesis efforts have been shown to work on solid supports. This technology greatly
improved the ability to synthesize large numbers of compounds in parallel, while si-
multaneously creating a pseudo-dilution effect which advantages MC formation over
oligomerization (Marsault and Peterson, 2011; Madsen and Clausen, 2011). Solid
phase methods have been used to create large, diverse screening libraries—resulting
7in the identification of inhibitors—ranging from 10,000 peptidomimetic MCs (Jeffer-
son et al., 2002) up to >30,000 MC compounds (Marsault et al., 2008; Marcaurelle
et al., 2010). Another strategy for MC screening library generation is to use biol-
ogy inspired technology, including mRNA display and synthetic biology approaches
(Terret, 2010; Josephson et al., 2014). A particularly promising technology for macro-
cycle libraries is DNA-Templated Organic Synthesis (DTS), developed in the Liu lab
at Harvard (Gartner et al., 2004; Li and Liu, 2004) and commercialized by Ensemble
Therapeutics (www.ensemblediscovery.com). DTS uses the natural annealing of DNA
strands to bring substrates into reaction proximity and facilitate ring closing, with
the specificity of DNA sequence pairing providing easy organization and identifica-
tion. Liu and coworkers were able to create a MC library of >13,000 compounds, and
validated the ability of their method to generate viable druglike MCs by identifying
a kinase inhibitor (Tse et al., 2008; Kleiner et al., 2010). Ensemble Therapeutics was
later able to use this technology to build a library of 160K MCs to investigate XIAP,
a difficult PPI target, successfully identifying an antagonist (Connors et al., 2015).
It should be noted that, though not as prodigious as the solid phase or bio-anchored
methods, there has also been some successful MC diversity/library creation as a re-
sult of advances in solution phase parallel synthesis techniques (Madsen and Clausen,
2011; Bogdan and James, 2011). Again, only a few high profile examples of novel
methods for MC library development and reaction condition improvements are de-
scribed here; an extensive account of synthetic techniques for diversifying compounds
can be found in recent reviews (Terret, 2010; Marsault and Peterson, 2011; Madsen
and Clausen, 2011; Mallinson and Collins, 2012; Yudin, 2015). It is with these types
of synthetic methodology advancements and technologies, where large scale MC li-
braries can be created and promising scaffolds can be readily—and reliably—explored
and modified, that synthetic MC drugs have really become a viable class for broad
8use by the pharmaceutical industry.
Understanding MC Biochemistry and Bioavailability
Perhaps the most important factor for the (re)acceptance of MCs, both novel syn-
thetic and natural product based, as a potential drug class has been advances in
our understanding of MC biochemistry and their potential to function where tradi-
tional drugs have failed. The increasing number of medicinally relevant MCs being
discovered, and heading into various stages of clinical trials, has brought along an
interest in the reasons for their success. This interest resulted in a surge in investiga-
tion of their behavior and attributes, both with protein targets and intramolecularly
(Yudin, 2015). The goal of these studies is to discern why these MCs succeed in
what was considered “undruggable” space, so the lessons can be applied to future
drug discovery efforts. For a long time, medicinally relevant MC compounds were
simply considered as bigger versions of small molecules, but they are now coming to
be recognized for their access to a privileged chemical space. The current notion is
that conformational restriction created by cyclization may afford MCs wider target
application, better target selectivity and potency, and improved oral bioavailability,
compared to acyclic analogs. MCs are not strictly rigid compounds though, and often
contain numerous partially rotatable bonds in the main cycle, as well as fully rotat-
able functionalities on side chains. It has been suggested that this balance between
structural pre-organization and flexibility reduces the entropic cost of binding to a
receptor (Driggers et al., 2008; Mallinson and Collins, 2012), though cyclization of an
acyclic analog does not necessarily effect better binding (DeLorbe et al., 2010). The
constraints on flexibility are also thought to aid in membrane permeation by allowing
for conformation switching to create intramolecular hydrogen bonds and reduce the
energetic cost associated with amide desolvation (Rezai et al., 2006). The increased
passive membrane permeability that can result confers greater bioavailability com-
9pared to an acyclic compound of similar size and composition. Work has also been
done demonstrating that features of the cycle backbone and sidechains can affect the
passive permeability and bioavailability of cyclic peptides, including conformation
determining stereochemistry and N -methylation (White et al., 2011; Bockus et al.,
2013), and the positioning of bulky side side chains that create steric occlusion of
backbone polar groups (Hewitt et al., 2015; Nielsen et al., 2014).
Macrocycles are now seen to hold great promise for drug discovery and design
campaigns. For the case of difficult targets, such as PPIs, MCs appear to occupy a
“sweet spot” between small molecules, which often cannot strongly bind the large and
shallow binding site to produce inhibition, and very large biological drugs, which suffer
difficulties in cell penetration and oral bioavailability. The possibility of accessing
what were previously seen as undruggable targets has made MCs attractive, and
multiple small biotech startups have been established solely to develop synthetic
methods for large scale MC production and analysis. The potential of this class of
compounds seems to be leading to important changes in the pharmaceutical industry,
and will likely have a continued impact going forward.
1.2 FTMap
In addition to considering which structures and chemotypes will make for a good
macrocycle drug, it is important to understand how these compounds interact with
their target protein. The ability of MCs to bind to classically difficult targets suggests
that their interaction with those proteins may differ from that of traditional small
molecule drugs with traditional targets. It would be useful to discover if there any
features in the binding sites of the proteins in question that make them predisposed
to binding MC compounds. In this dissertation work, fragment-based computational
tools for hot spot investigation were used to explore this question, so an overview of
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binding site hot spots and molecular fragment probes as tools for drug discovery is
provided here.
1.2.1 Hotspots and Fragment Based Lead Discovery
Fragment based lead discovery (FBLD) has become a widespread tool in drug discov-
ery campaigns and often takes advantage of the concept of “hot spots” in a binding
site. Initially, these binding region subsites were identified by studying PPI interfaces
through alanine scanning mutagenesis, where interface residues are serially mutated
to alanine and the impact on binding affinity is measured (Clackson and Wells, 1995).
This study showed that the binding energy at the interface of human growth hormone
and it’s bound receptor was primarily localized in small, binding energy “hot spots”
rather than being distributed evenly across the binding interface. With hot spots
well established as regions of the binding interface that contribute a disproportionate
amount of the binding free energy, they became targets for drug binding (Bogan and
Thorn, 1998; DeLano, 2002; Moreira et al., 2007).
Shortly after hot spots were identified at PPI interfaces, it was shown that a type
of hot spot can also be observed for drug-sized ligand binding sites on proteins. Ex-
perimental techniques, independently developed by two labs, found that energetically
favorable susbsites in the binding pocket could be identified using fragment-sized
molecules. The multiple solvent crystal structures (MSCS) method determines the
X-ray structures of a protein soaked with several organic solvents, individually, that
are then superimposed to identify sites where multiple probe molecules overlap (Allen
et al., 1996; Mattos and Ringe, 1996). Mattos and co-workers postulated that the
hot spots they identified with overlapping solvent probes might be analogous to those
found in the PPI interface work. The other experimental method to identify ligand-
binding subsites is structure-activity relationship by nuclear magnetic resonance (SAR
by NMR), which uses NMR to screen a library of fragment-sized compounds (average
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MW=213) for molecules that bind to the target protein (Shuker et al., 1996; Hajduk
et al., 1997). Lead compounds are then generated using the chemical and orientation
binding information from fragments bound in proximal subsites. Both of these tech-
niques established the presence of discrete, energetically important subsites within
ligand binding sites on the protein.
Once it was recognized that high affinity subsites existed in ligand binding sites,
and that fragment molecules could be used to find them, drug discovery campaigns
focusing on fragment based leads burgeoned. These new discovery campaigns de-
veloped and used screening libraries exclusively containing fragment-sized molecules,
with compounds having a typical MW of 100–250 Da (Carr and Jhoti, 2002; Erlan-
son et al., 2004; Rees et al., 2004; Hubbard and Murray, 2011; Zartler and Shapiro,
2005; Hajduk and Greer, 2007). The advent of sensitive biophysical screening using
NMR and X-ray crystallography allowed for the detection of fragment binding, which
typically occurs with binding affinities in the mM range (as opposed to the low µM
range of drug-sized compound screens). Interest in fragment-based screening grew
so much that guidelines for constructing libraries were purposed (Congreve et al.,
2003), and the likelihood for fragments to be optimized into a successful therapeutic
lead was assessed (Hajduk, 2006). Moreover, in a study using SAR by NMR on a
diverse protein set, Hajduk and co-workers found that the overwhelming majority of
fragments that bound were found to occupy a site known to bind small molecules
(Hajduk et al., 2005a). This supported the idea that in addition to lead discovery,
fragment screens might be employed to locate potential drug binding sites on novel
protein targets.
When fragment hits are identified they can be developed into leads via linking,
evolution, or optimization (illustrated in Figure 1·2). Fragment linking is when two
or more fragments that bind in different parts of the binding pocket are close enough
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to be chemically linked together. While the benefits of this method to binding affinity
can be substantial, it has been difficult to achieve in practice. Definitive structural
data on the orientations of the fragments is needed in order to plan effective linking,
and a synthesizable linker that maintains the fragments in their required orientation
is not always possible. Evolution of hits involves building up fragment into a larger
molecule with functional groups that access and interact with additional regions of
the binding site. Fragment evolution is widely used as it is a fairly straightforward
approach and requires only one fragment hit. Optimization of fragments focuses
on improvement of druglike properties—in addition to binding affinity—with small
structural changes. The optimized fragment then replaces the original fragment hit
in the same larger lead molecule that was designed around the fragment. Though
optimization helps compounds stay within good druglike parameters, it can be diffi-
cult to increase affinity while keeping compounds in the fragment size range. All of
these lead development methods have successful examples of taking a fragment hit
to a druglike lead molecule with good binding affinity (Rees et al., 2004; Orita et al.,
2011).
The new FBLD strategies arose as an alternative to traditional high through-
put screening (HTS) hit identification, where libraries contain compounds that are
already “druglike” with respect to MW and other features. Some of the main ele-
ments of fragment based methods that made them advantageous are: (1) Efficient use
of chemical space—the number of potential fragments is many orders of magnitude
smaller than the number of druglike compounds, but can combinatorially achieve
most pre-assembled compounds, therefore a more diverse space can be sampled using
less molecules (Congreve et al., 2008; Leach and Hann, 2011). (2) Efficient binders—
fragments have a high proportion of atoms interacting directly at the binding site,
resulting in a high binding energy per atom (Congreve et al., 2008; Hopkins et al.,
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Figure 1·2: How common FBLD strategies compare with traditional methods. A.
Representation of a low quality traditional HTS hit. The molecule makes multiple
low efficiency surface contacts, but does not make high quality interactions within
the pockets. B. Fragment evolution. A fragment hit (1) is evolved by growing
the molecule into a nearby hot spot; the intermediate segment also makes good
surface contact. C. Fragment linking. Fragments 1 & 2 bind neighboring pocket
hot spots and are joined together by a linker that allows the moieties identified
from the individual fragments to interact with their respective sites in the correct
orientation. D. Fragment optimization. A lead molecule identified from a fragment
(1) is re-engineered with optimized version of original fragment (3). Adapted from
Rees, et. al. FBLD review (Rees et al., 2004).
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2004; Kuntz et al., 1999). (3) Higher binding probabilities—the decreased molecu-
lar complexity of fragments means a lower number of conditions need to be met for
favorable binding to the target site; it also avoids some shape based steric clashes
that would preclude them from sites entirely (Hann et al., 2001; Leach and Hann,
2011; Hubbard and Murray, 2011). (4) Greater leeway for optimization—the opti-
mization process tends to increase MW and lipophilicity so fragment starting points
leave greater chemical space to increase potency before running into adverse effects
heavy, highly lipophilic compounds suffer (Vieth et al., 2004; Hann et al., 2001; Rees
et al., 2004).
Experimental hot spot detection and FBLD have become useful and important
techniques in the drug discovery world, but they do have some limitations that may
be complemented by computational methods. While the biochemical and biophysical
assays required for fragment screening have improved in efficiency over the years, they
can still be expensive, requiring specialized instrumentation as well as the curation
and upkeep of fragment libraries. Also, empirical screening is limited by both the
number of molecules that can be screened in a reasonable amount of time and what
compounds are available in sufficient quantity. Such limitations do not apply to
computational fragment screens.
Computational methods have long been explored as a way to aid in the drug dis-
covery process. Compounds involved in FBLD campaigns are particularly appealing
because of their lower complexity, which makes them less computationally intensive
to model. Computers can aid in general fragment library design and filtering, as well
as in the investigation of specific binding sites for features used to prioritize screens
of fragment (or drug-sized) leads, and/or provide lead optimization insights. For ini-
tial library curation, algorithms can be used to filter compound collections based on
structural criteria, and some of the related physicochemical properties, using machine
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readable formats, such as SMILES (Simplified Molecular Input Line Entry System,
www.daylight.com) (Weininger et al., 1989). An example of such criteria would be
the “Rule of Three” (RO3), a set of guidelines suggesting fragments used in screen-
ing should possess MW ≤ 300, hydrogen bond donors and acceptors each numbering
≤ 3, and a cLogP ≤ 3 (Congreve et al., 2003). Software looking at two-dimensional
molecular fingerprints—a way of using patterns to represent structural features of
molecules for comparison—have been used to evaluate the molecular diversity in a
library and eliminate redundancy using substructures and chemical environment infor-
mation (Daylight Chemical Systems Inc., 2008; Rogers and Hahn, 2010). Screening
libraries can also be filtered and enriched to focus on molecules containing certain
functional groups, informed by the chemical moieties found in known substrates or
cofactors of the target protein. Such cheminformatics methods are routinely used
in the pharmaceutical industry, and advances in computing power, speed, and data
storage are making them better and more useful tools.
Even though the use of computational methods for data mining, assessment, and
curation of compound libraries is well established in drug discovery campaigns, their
use in target exploration and lead development have been more limited. Virtual
screening techniques have been developed and implemented to aid both in the dis-
covery and optimization process when developing a new drug. But deriving binding
site information from a protein is a vastly complex problem, resulting in various ap-
proaches to the solution, with varying focus on the different aspects involved. The use
of in silico screening of fragments on three-dimensional protein models includes soft-
ware such as MCSS, GOLD, and Glide (among many others) (Miranker and Karplus,
1991; Verdonk et al., 2003; Friesner et al., 2004), which dock a compound into the
binding site in various positions and rank the poses by energy. Computational screen-
ing methods like these have been used as a part of drug design campaigns to prioritize
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fragments that lead to experimentally validated hits (Evers and Klabunde, 2005).
Because of their small size, doubts have been raised about the use of docking for
fragments concerning the potential for binding mode promiscuity as well as biases
in scoring functions. However, comparisons of docked fragments to their crystallo-
graphic structures have demonstrated high geometric fidelity (Teotico et al., 2009;
Chen and Shoichet, 2009), showing that virtual methods can still serve to prioritize
screening fragments or rule out compounds ill-fitted to the binding site. An important
limitation of in silico screening, however, is the typical lack of hydrogens in X-ray pro-
tein structures. The missing hydrogens can result in ambiguity of amide-containing
side chains and requires some user intervention, but many of the screening software
packages help guide this process. It should also be noted that the available methods
for in silico fragment screening often use a rigid target structure, which has the po-
tential for false positives or missed leads if the available crystallographic “snapshot”
of a dynamic protein is not representative of the functional conformation. But work
has been done towards incorporating some conformational flexibility in tandem with
fragment docking/mapping (Ekonomiuk et al., 2009; Ivetac and McCammon, 2012;
Grove et al., 2013). A benefit to virtual fragment screening is that it is not limited
to commercially available or synthetically tractable fragments, so most any pharma-
cophore or substructure can be tested. These virtual-only fragments could be used as
a basis for new synthetic designs, or could be used in a substructure search of existing
compounds (O’Boyle et al., 2011). The above is by no means an exhaustive discus-
sion of the available computational aids to fragment based studies, as there have been
numerous private and academic algorithms and software packages developed towards
FBLD efforts.
Once initial hits are experimentally identified, computational approaches can be
used to assist in the progression of fragments to leads. Virtual fragment-to-lead
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methods are mainly employed through algorithmic detection of nearby hot spots for
indication of best growth direction (Hall et al., 2012b; Chemical Computing Group,
2014), or through identification of fragment pairs that have the right geometry for
potential linking followed by assistance with the linker design process (Cambridge
Crystallographic Data Centre, 2012; Thompson et al., 2008). Virtual linking allevi-
ates the need for high resolution structural imaging of bound fragments for all early
hits, which can be expensive, time consuming, and not always feasible. Software to
aid in fragment growth varies from general growth vector detection and optimization
to iterative docking cycles of specific compounds. Even though the computational
methods discussed here have begun to be implemented as tools in drug discovery and
development, it should be noted that such methods are generally used as idea gen-
erators, aids in prioritization or refinement/enrichment techniques. Limitations from
protein structure imaging as well as the enormous complexity of molecular interac-
tions mean virtual fragment methods are unlikely to reliably produce novel ligands
with nanomolar activity completely on their own.
Another area that has been the focus of fragment-based computational methods
is the characterization of protein druggability through identification of binding hot
spots on a target protein. There are estimates that only 10% of genes in the hu-
man genome are druggable—that is, able to bind a typical drug-sized molecule with
good affinity (typically below 10µM). Moreover, genes that are both druggable and
pharmaceutically relevant possibly comprise only 2–5% (Hopkins and Groom, 2002).
Thus, the ability to reliably assess a protein’s potential as a successful target for drug
design prior to initiating a full screening campaign would be highly valuable. A reli-
able way to identify the site where a druglike compound is most likely to bind, and
how strongly, before the lead design process even begins has been long sought after
in the computational community, for both traditional HTS and FBLD. For a long
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time, target selection for new drug campaigns relied heavily on finding proteins with
known small molecule binders, and drugs were then created to compete for binding
with that endogenous molecule (Drews, 2000; Hopkins and Groom, 2002). Once the
human genome was sequenced there was a lot of interest in the potential for genetics
to bring a wave of novel drug targets, as data on common sequences and protein fam-
ilies led to further understanding of some active sites (Walke et al., 2001; Reiss, 2001;
Caron et al., 2001; Chanda and Caldwell, 2003). However, it was quickly recognized
that the new genetic data alone, though helpful in many ways, would not remedy the
decline in new drug approvals—with some even suggesting it caused more problems
by shifting the field too far into target-based drug discovery, clogging the pipeline
with unvalidated targets (Murcko and Caron, 2002; Russ and Lampel, 2005; Sams-
Dodd, 2005). Progress in understanding drug targets also advanced with the increase
in the number of high resolution 3D X-ray crystal structures, which promoted anal-
ysis of the sites on proteins that bind small molecules (Hajduk et al., 2005b). Both
genetic sequence information and structural information have led to the development
of numerous algorithms that try to identify small molecule binding sites. These in
silico methods have been based on cavity or pocket size/shape, geometric and physic-
ochemical properties, and amino acid composition, with the most successful using a
combination of these features (Hendlich et al., 1997; Brenke et al., 2009; Halgren,
2008; Nayal and Honig, 2006; Cheng et al., 2007; Kalidas and Chandra, 2008; Koes
and Camacho, 2012).
1.2.2 Overview of the FTMap Algorithm
In the work discussed in Chapters 2–4 the FTMap (fast Fourier Transform MAPping)
algorithm (Brenke et al., 2009) was used extensively; an overview of the process and
a brief discussion of its application is provided here. The description of the method
here pertains to the server version of FTMap (available at ftmap.bu.edu), which is
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Figure 1·3: Overview of the FTMap algorithm. A. Flowchart outlining the steps
of the algorithm. B. Structures of the 16 molecular probes used for standard global
mapping of proteins. C. Illustration of the identification of a consensus site using
two probes. The green circles and orange hexagons each represent a probe type.
The bottom panel depicts the consensus site where clusters from the two types of
probes overlap.
based on the original publication; any modifications to the process as used in this
work are noted in the relevant chapters. A flowchart of the main steps is illustrated
in Figure 1·3 A.
Protein Selection and Preparation. The mapping program is run on X-
ray crystal structures in Protein Data Bank (PDB) format (Berman et al., 2000).
Any bound ligands or crystallographic waters (atoms with the label HETATM) are
discarded prior to the calculations. Parameters for common metals and some cofactors
are available on the server, but their incorporation must be specified by the user.
FFT Rigid Body Docking Step. A set of 16 small molecule probes (depicted in
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Figure 1·3 B) is used to globally sample the protein. Each probe is placed on a dense
grid around the protein and fast Fourier transform (FFT) is used to sample billions
of docked conformations. This method does not require any a priori information on
the ligand binding site; only the atomic coordinates of the probes and the protein are
used to perform the calculations. The 2000 lowest energy poses are retained for the
minimization step.
Off-grid Minimization For each probe progressed from the docking step, the free
energy of the probe-protein complex is minimized using the CHARMM (Brooks et al.,
2009) potential and analytic continuum electrostatics (ACE) (Schaefer and Karplus,
1996) model. During the energy minimization the probe atoms and the polar hydrogen
atoms of the protein are allowed to move while the rest of the protein atoms are held
fixed. Minimized poses with positive energy are discarded.
Generating Consensus Clusters For each probe type, the individual probes are
clustered using a simple greedy algorithm (a heuristic technique that focuses on the
locally optimum choice (Cormen et al., 2001)), with the lowest energy pose selected
for the cluster center. The members identified for this cluster are then removed (to
prevent double counting), and the process is repeated until the entire set of poses of
that probe type is exhausted. Clusters with less than 10 members are discarded. The
probe clusters are ranked on the basis of their average free energy and the six lowest
are used for consensus clustering. Consensus clusters are generated by grouping
nearby single probe type clusters based on distances of the centers of mass of the
clusters, with the cluster having the greatest number of neighbors selected as CS1
(consensus site 1). As with the probe clusters, members of each defined CS are
removed to prevent double counting and the process repeated until all individual
probe clusters are assigned to a CS. The consensus clustering method of FTMap
is analogous to the experimental method of MSCS, where small molecule organic
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probes are soaked into a protein crystal and then the results of the each are overlaid
to identify sites where multiple probes bind (Figure 1·4).
1.2.3 FTMap as a Successful Predictive Tool
FTMap has been used to successfully determine primary ligand binding sites on pro-
teins, even on the unbound structure, and the hot spots identified by the CSs have
been shown to agree with those found by X-ray or NMR experimental fragment
screening techniques (Brenke et al., 2009; Chuang et al., 2009; Landon et al., 2009;
Ngan et al., 2012b; Kozakov et al., 2011; Hall et al., 2012b). Figure 1·4 depicts the
original mapping work from the Vajda group (Brenke et al., 2009) on porcine pan-
creatic elastase, where FTMap identified all five subsites that bound small organic
molecules determined by MSCS (Allen et al., 1996; Mattos et al., 2006). Additional
work in the Vajda lab demonstrated the ability of FTMap to provide information on
the structure of secondary hot spots that corresponded to locations of experimentally
demonstrated favorable lead growth (Hall et al., 2012b). This work also further vali-
dated its power to predict druggability with the placement of the main CS hot spot.
As the algorithm was validated on more targets with known inhibitors, “druggable”
targets were shown to have a binding site with at least one CS with population >16
probes plus at least one other CS with population >5 within 7 A˚ (Hall et al., 2012a).
FTMap has been used to investigate both PPI and peptide interfaces (Kozakov et al.,
2011; Lavi et al., 2013). Recently, FTMap was implemented in conjunction with an
algorithm that identifies flexible residues within the binding site and allows them
to move into alternate conformations as a way to attain improved mapping on apo
protein structures (Grove et al., 2013). The success of FTMap in identifying primary
hot spots and important neighboring hot spots of the same binding site made it a
useful tool for analyzing the proteins that bind the MCs of our study.
22
Figure 1·4: Hot spot analysis on elastase (PDB code 1ELA) by MSCS and FTMap.
A. Probe molecules in the S1 pocket of elastase, based on superimposing elastase
structures solved in acetone, dimethylformamide, 5-hexene-1,2-diol, isopropanol,
ethanol and trifluoroethanol. Probes are colored by molecule. B. Probe molecules
in the active site of elastase, based on superimposing the structures listed in (A).
The probes are colored by subsite. C. Centers of probe clusters in the largest CS
of elastase, located in the S1 pocket, from computational mapping using the 16
probes. Probes are color-coded to distinguish between different probe structures
D. Centers of probe clusters in the five CSs located in the active site of elastase
as determined by the mapping. The probes are color-coded for different CSs: CS1,
cyan; CS4, salmon; CS5, sky blue; CS7, orange; and CS8, pale green. Adapted from
Brenke et al., 2009.
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1.3 NEMO
In Chapter 3 the interaction between nuclear factor-kappa B (NF-κB) essential mod-
ulator (NEMO) and IKKβ was the target for inhibitor design and hot spot mapping.
An overview of the biology of this system and what is currently known about the
IKK structure is provided here.
1.3.1 NEMO Biology and Structure
Since its discovery almost 30 years ago, the NF-κB signaling pathway has been thor-
oughly studied and remains of interest because of its role in regulating gene ex-
pression pathways relating to important cellular and organismal processes such as
inflammation, cellular stress response, and cell proliferation and survival. Due to its
involvement in so many cell processes, mis-regulation of the NF-κB pathway is linked
to many diseases, particularly ones associated with inflammation, immunodeficiency,
and cancer (Gilmore, 2006; Courtois and Gilmore, 2006). A therapeutic target of
particular interest is the scaffolding protein NF-κB essential modulator (NEMO), an
important regulatory component of the NF-κB pathway. Together with the IKKα
and IKKβ kinase subunits NEMO forms the IκB kinase (IKK) complex (where IκB
is inhibitor of κB), which is directly involved in the activation of NF-κB through
regulation of IκB proteins by phosphorylation. IκBs are normally bound to NF-κB,
sequestering it in an inactive state in the cytoplasm; phosphorylation of IκB signals
its degradation, releasing NF-κB to enter the nucleus (Gilmore, 2006; Israel, 2010;
Hinz and Scheidereit, 2013). This is known as the canonical NF-κB signaling pathway
(see Figure 1·5). Interruption of IKK formation at the PPI interface of the IKK α/β
subunits with NEMO is the therapeutic goal.
The IKK complex has attracted a lot of attention because of its role in the NF-κB
pathway, but it has been difficult to study, as the precise arrangement and composi-
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Figure 1·5: The NF-κB signaling pathway. Image reproduced from Gilmore et al.
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tion of the complex remains unclear. Although the full three dimensional structure
of NEMO and the IKK complex is not resolved, much has still been learned about
the structure and arrangement of the IKK complex. Multiple unique structures have
been solved for the different regions of NEMO, collectively depicting much of the
protein (Rushe et al., 2008; Bagneris et al., 2008; Cordier et al., 2009; Rahighi et al.,
2009; Grubisha et al., 2010). From these solved portions of the protein, the structure
of NEMO is thought to mostly consist of α-helical coiled coils in an elongated form.
NEMO includes two coiled-coil regions (CC1 and CC2), a leucine zipper (LZ), and a
C-terminal zinc finger (ZF) (Figure 1·6A). The IKK complex has been shown to con-
tain a NEMO dimer with two kinase chains, and exists in forms containing an IKKα/β
heterodimer as well as both IKKα and IKKβ homodimers (Hinz and Scheidereit,
2013). Phosphorylation of IKKβ is necessary for activation of the canonical pathway
(Israel, 2010) and we will focus on the IKKβ homodimer complex in this work. The
CC1 region of NEMO interacts with residues 701–745 of the IKKβ C-terminal region
(see Figure 1·6B), where there is a six amino acid sequence (L737DWSWL742) criti-
cal for complex formation, known as the NEMO binding domain (NBD) (May et al.,
2000; Rushe et al., 2008; Israel, 2010). An 11-amino-acid peptide containing the NBD
was shown to interrupt the IKK complex formation and act as an inhibitor of NF-κB,
and mutational analysis identified D738, W739, and W741 of the NBD as critical for
binding (May et al., 2002). A later study of the role individual IKKβ residues played
in binding, by alanine scanning mutagenesis and computational methods, confirmed
the importance of the NBD and quantified the energetic impact of the direct contact
residues (Golden et al., 2013).
In 2008 Rushe et al. determined the X-ray co-crystal structure of the minimal
associating domains of NEMO and IKKβ, providing alignment, orientation, and in-
terface details for the region containing the NBD (Rushe et al., 2008). They found
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Figure 1·6: Interaction of NEMO with IKKβ. A. Schematic representation of the
NEMO domain structures. The bar underneath indicates the region of interaction
with IKKβ. B. Structure of the NEMO(44–111) fragment (wheat) with IKKβ(701–
745) peptides bound (pink and yellow); PDB code 3BRV. C. The region including
the NBD is highlighted and enlarged, with direct contact residues Phe734, Trp739,
and Trp741 shown as sticks and colored in red.
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that the complex is arranged as a parallel set of α helices (see Figure 1·6), and showed
that only a length of residues in NEMO comprising amino acids 44–111 is necessary
for IKKβ binding. Importantly, Rushe and co-workers found that the NEMO44−111
fragment only became ordered in the presence of an IKKα or IKKβ peptide, making
NMR or X-ray studies of the unliganded binding site difficult. It can also be noted
from this crystal structure that there is an asymmetry to the complex, meaning the
corresponding side chains in the two IKKβ chains do not form an identical alignment
and orientation along the specificity pockets of NEMO, which has implications for
drug design strategies (discussed in Chapter 3).
The research covered in this dissertation is centered on advancing our understand-
ing of macrocycles as potential drugs, with a focus on the development and validation
of computational tools to facilitate such investigations. In Chapter 2 we ask if natural
product MCs can help inform the design of new synthetic MC drugs through study
of the structure and composition of known MC inhibitors as well as their interactions
with their target proteins. In Chapter 3 the lessons learned from the natural product
MC study are coupled with an investigation of binding hot spots on NEMO44−111 and
applied to the design scheme for a synthetic MC inhibitor of NEMO/IKKβ binding.
For both Chapters 2 and 3 we use the FTMap software to study and analyze the
binding sites on the proteins of interest. Finally, in Chapter 4 we explore the expan-
sion of chemotypes used in the FTMap probe library in an attempt to extract more
information about binding site hot spots.
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Chapter 2
Analysis of Protein-Macrocycle Complexes
2.1 Introduction
Although there is wide and increasing interest in the use of synthetic macrocycle (MC)
compounds as drugs (see Section 1.1.2), limited information is available to aid the
design of MCs with good binding activity and bioavailability. Even when restricted to
the medicinal chemistry use of “macrocycle,” which focuses on compounds resembling
those cyclic drugs derived from natural products (Section 1.1), the term covers a wide
and varied set of chemical structures. However, only a small subset of these MCs
presumably have acceptable structures with respect to target binding and ADME
(absorption, distribution, metabolism, excretion) properties. It would therefore be
useful to know whether there are structural or physicochemical features that tend to
benefit, or detract from, the pharmacological potential of a macrocyclic inhibitor. In
this work we looked to natural product MCs—a long standing source of successful
drugs and lead inspiration—to see what lessons for future compound design could be
learned from potent compounds refined by nature. For our investigation of natural
product MCs we assessed characteristics both of the MCs alone (e.g. ring size, cLogP,
types of heavy atoms), and how the MCs interacted with their target protein (e.g.
buried surface area, binding topology).
This chapter will cover the work I did towards the development of design guidelines
for synthetic macrocycles based on the analysis of natural product macrocycles and
their protein complexes. The analysis consisted of two main parts: the composition
and physicochemical properties of the MC compounds, and the binding modes and
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atom contributions of the MC with its protein target. Additionally, I investigated
the proteins that bind macrocycles in order to identify any binding site features that
distinguish them from sites that bind conventional drug ligands. A summary of the
guidelines proposed for synthetic libraries, following from the results, is included at
the end of the chapter. For this study, the physicochemical properties of the MC test
set compounds and of approved MC drugs were analyzed by Dr. Adrian Whitty and
Dr. Spandan Chennamadhavuni, respectively. The algorithm used to identify the
binding surfaces and binding site atoms was developed by Dr. Dmitri Beglov; the
scripts to determine ligand occupancy of a consensus site were developed by Scott
Mottarella. This work was published in Nature Chemical Biology (Villar et al., 2014),
though it is covered here in greater detail.
2.2 The Macrocycle Test Set
2.2.1 Selection Criteria
To study the interaction of natural product MCs with their target proteins a set
of X-ray co-crystal structures of such complexes was identified. Selection began by
identifying Protein Data Bank (PDB) entries containing a bound ligand with a ring
of 14 or more atoms, where ring atoms were defined as atoms in the continuous,
sigma-bonded chain that defines the macrocyclic scaffold (see section 2.3.2 for details
on defining the ring). The resulting set of complexes was then further filtered using
a series of criteria intended to ensure a representative set and remove redundancies,
as detailed below.
Only complexes containing natural product MC compounds or compounds derived
from natural product MCs were retained, which excluded ligands that were discovered
via cyclization of acyclic leads, even if the acyclic lead was a natural product. Because
the goal was to identify properties that could inform synthetic MC inhibitor design,
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only MCs that had chemical structures likely to be useful in drugs and, more specif-
ically, function as inhibitors of their target protein, were kept (eg. no substrates,
coordinated metal cofactors, RNA binders, etc...). To minimize redundancy, if a
compound had a series of closely related analogs bound to the same protein, one rep-
resentative structure was selected, prioritizing the original compound— except where
crystal resolution or B factors of the original compound complex indicated a poorer
quality structure, but the mode and level of inhibition of the analog were near iden-
tical. For cases where identical MCs bound orthologs of a protein, one representative
was selected to avoid bias, prioritizing the human protein where possible. Structures
of the same MC complexed to distinct proteins, or the same protein bound to dif-
ferent MC ligands, were not considered to be duplicates, because a different binding
partner usually effects a distinct binding mode. For instances of multiple versions of
identical ligand-protein pairs, structures were again prioritized by a combination of
overall resolution and resolution of the ligand atoms and protein binding site atoms
(i.e. structures containing a dual occupancy for a residue near a ligand atom were
ranked lower). To ensure only realistic inhibitor interactions and binding modes were
studied, complexes containing a mutation in the binding site were excluded, as well
as those with a mutation known or intended to change the topology of the binding
site. Complexes where binding site conformation was known or determined to be
dependent on crystal contacts were also excluded. No structures with a resolution
>3.0 A˚ were allowed, though <2.5 A˚ was preferred and many were <2 A˚. It should
be noted that for the case of actin, numerous MC co-crystal complexes were found
(>10), but many of the MC ligands could be grouped by similarities in structure
and/or targeted region (e.g ring composition, type of “tail” substituent, side of the
binding site targeted, etc.). In this case a representative example of each related set
of complexes was chosen so as not to bias set composition with many ligands of a
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single protein. For actin binding MC groups with multiple complex structures having
good resolution, no mutations, etc. available, we tried to select the MCs that were
more thoroughly studied and validated as inhibitors, with a better understanding of
the inhibitors’ mode of action.
2.2.2 Composition of the Final MC Test Set
Following application of the above selection criteria, our final MC test set was com-
posed of 22 distinct MC-protein complexes, encompassing 19 distinct MCs and 13
distinct proteins (plus one ortholog, bound to two distinct MCs). The final set con-
tained MC compounds ranging in ring sizes of 14–35 atoms, with molecular weights of
365–1291 Da. The complexes are compiled in Table 2.1, including their corresponding
PDB ID code, and the MC structures can be seen in Figures 2·1 and 2·2. A full list
of the PDB entries containing a protein-MC complex that were considered during
compilation of the test, and their reasons for exclusion, can be found in Table A.1 in
Appendix A.
To assess how well our relatively small test set represented natural product MCs
generally, we compared it to the 3747 natural product MCs analyzed by Wessjohann
and colleagues (Wessjohann et al., 2005), as well as to the 44 approved MC drugs
(primarily obtained from the ChEMBL database (Gaulton et al., 2012) ). A compar-
ison of ring sizes, depicted in Figure 2·3, shows that our set corresponds well with
both reference sets, and can be considered fairly representative of the range of natural
product MCs. The main exception is for ring sizes 13–15, which is under-represented
in the test set compared to the Wessjohann set; the population of test set rings sized
13–15 is similar to that of the approved drugs set. Wessjohann suggests this differ-
ence in the smallest ring sizes is a result of an abundance of diterpenoids and their
derivatives in nature. Moreover, many of these smallest ring MCs contain structures
not relevant to medicinal chemistry, therefore making them unlikely to be considered
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Figure 2·1: The chemical structures of the large MCs.
33
Figure 2·1: The large MC structures, continued.
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Table 2.1: A list of the macrocycle-protein complexes in the test set.
Macrocycle Abbrv. Protein PDB ID
Kabiramide C KabC Actin 1qz5
Latrunculin B lab Actin 2q0u
Pectenotoxin 2 PTX-2 Actin 2q0r
Reidispongiolide A rga Acitn 2asm
Argadin rig Chitinase 1waw
Argifin rag Chitinase 1wb0
Cyclosporine A CsA Cyclophilin 1cwa
Sanglifehrin A SfA Cyclophilin 1ynd
FK506 FKBP 2fke
Rapamycin rap FKBP 2dg3
Geldanamycin gdm hHsp90 1yet
Pochoxime A jzb hHsp90 3inw
Macbecin bc2 yHsp90 2vwc
Arylomycin A2 aryl2 SPase 1t7d
GE2270A gea EF-TU 1d8t
Nodularin R nodR PP1a 3e7a
Scyptolin A scypA Pancreatic Elastase 1okx
Soraphen A s1a Accoa Carboxylase 3gid
Radicicol rdc yHsp90 1bgq
Radicicol rdc PDK3 2q8i
Radicicol rdc PhoQ 3cgy
Radicicol rdc Topoisomerase 2hkj
in drug development scenarios. Another difference is that the test set slightly over-
represents very large rings, 34–36 ring atoms, relative to the natural products set,
though the relative amount of large ring compounds is similar to that for approved
MC drugs.
2.3 Structural Features and Physicochemical Characteristics of the Final
Test Set
2.3.1 Natural Bifurcation of the Test Set Into “Large” and “Small” MCs
After the set of protein-MC complexes was compiled a natural split in the molecular
weights was observed, which became useful for categorizing the MCs. The first size
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Figure 2·2: The chemical structures of the small MCs.
Figure 2·3: Distribution of ring sizes of the MCs in the test set compared to the
extensive natural product MCs from Wessjohann and a set of approved MC drugs.
36
category included the “small” compounds, comprising the six MCs with molecular
weights < 600 Da, placing them within or close to the upper bounds of traditionally
“druglike” molecules (Lipinski et al., 1997). The “large” MCs were the 13 compounds
that had molecular weights > 600 Da, with most being much greater, which therefore
substantially violate the bounds of classic druglikeness. We were interested to deter-
mine if the similarity in size of the small MCs to conventional druglike molecules set
them apart from the large MCs in any way. To identify any trends or differences be-
tween the large and small MCs all of the compositional, physicochemical, and contact
data was analyzed for these two subsets separately, in addition to the test set as a
whole.
2.3.2 Definitions of the MC Structural Components
Due to the complex structure of many of the MCs it was useful to categorize the
heavy atoms in each MC by regional type, allowing us to analyze how different parts
within each molecule interact with the protein binding site. Three distinct regions
were defined: “ring atoms,” “peripheral atoms,” and “substituent atoms,” which
are depicted in Figure 2·4 on an example MC structure. Ring atoms are atoms in
the continuous, sigma-bonded chain of atoms that defines the macrocyclic scaffold.
In cases of compounds containing multiple cyclic sections with two or more sigma
bonds shared between them, the system is regarded as a fused ring. For these fused
rings the macrocyclic ring is considered to encompass both cycles, and comprises the
longest continuous cyclic sigma-bonded chain of atoms. An exception to this fused
definition is when the smaller fused ring is aromatic, then it is counted along the
shorter continuous side of sigma-bonded atoms. Where the fused rings share only a
single sigma bond, the macrocyclic chain will be considered to include only the larger
of the two rings, with the smaller fused ring considered as a substituent (see example
in Fig. 2·4). Peripheral atoms include any single heavy atom (and its associated
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Figure 2·4: Definition and distribution of the three structural regions of the test
set MCs. A. Heavy atoms of the MC categorized as ring atoms (black), peripheral
atoms (green), or substituents (blue). Illustrated using FK506 as an example. B.
Heavy atom populations for the different regions in the test set for large MCs and
C. small MCs.
hydrogens, if any) adjoining the main MC ring. This includes small groups such as
methyl, carbonyl, hydroxyl, and halogens. Substituent atoms are those which are part
of larger structures appended to the ring, i.e. having two or more heavy atoms. This
includes fused rings that only share a single sigma bond and fused rings which share
more than one sigma bond but are aromatic.
Analysis of the proportion of atoms contributed to the MCs by each region (ring,
peripheral, substituent) showed that the population of atoms by region was different
for the large and small MCs, particularly for substituents. For large MC compounds,
substituent atoms typically comprise around half of the structure (47± 13%), with
ring atoms accounting for only 38% and peripheral atoms 15% (Figure 2·4B). For
the small MCs it is the ring atoms which comprise around 50% of the structure,
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while substituents make up approximately 35% and peripheral atoms 15% (Figure
2·4C). This difference in atom arrangement between large and small MCs reflects
the fact that the all of the large MCs have at least one large substituent containing
at least eight heavy atoms (though most have a substituent of 12 or more atoms),
plus several small to medium-sized substituents arranged around the rest of the ring.
It is interesting to note that the peripheral atoms comprise the same proportion of
the structure for both the large and small MCs; they also tend to be fairly evenly
distributed around the ring. A full listing of the regional composition data for each
MC can be found in Table A.3 in Appendix A.
2.3.3 Analysis of the MC Set Using Traditional Physicochemical Prop-
erty Metrics
Many MCs that have become approved drugs reside in a strange category in the world
of drug discovery because they violate at least one, but often multiple, conventional
structural and physicochemical limits suggested for drug success. We evaluated the
test set in terms of these traditional benchmark property limits to determine whether
they displayed the trends of conventional oral drugs, approved MC drugs (both oral
and non-orally available), or some combination of both drug types. The proper-
ties of lipophilicity (cLogP), polar surface area (PSA), number of hydrogen bond
donors/acceptors (HBD/HBA), and number of rotatable bonds (NRB) were com-
pared, for the test set and the two drug sets, because they are typical criteria for
assessing the drug-likeness of a compound (Lipinski et al., 1997; Lipinski, 2000; Ve-
ber et al., 2002). For this comparison we also determined the relevant values for the
large and small MCs separately. The properties of each compound set are collected
in Table 2.2.
For the MC test set as a whole almost all of the RO5 properties were different from
those of both the MC drugs and the traditional oral drugs. The separation of test
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Table 2.2: RO5 properties of test set, MC drugs, and all oral drugs.∗
Class MW cLogP PSA (A˚2) HBD HBA NRB
MC Test Set 778 2.8 212 4.9 10.7 8.6
(n = 19) (476–1090) (-2.5–5.7) (104–296) (2–9) (6–13) (1–15)
Large 915 2.3 255 6.1 12.7 11.2
(n = 13) (676–1202) (-5.1–7.5) (178–322) (3–10) (11–15) (6–18)
Small 479 3.9 118 2.3 6.5 3.0
(n = 6) (396–559) (-3.5–4.5) (96–143) (2–2) (5–7) (1–5)
MC Drugs† 963 -0.2 303 8.7 14.4 11.8
(n = 44) (668–1269) (-7.2–6.8) (158–513) (2–17) (10–20) (3–23)
Orally
Available‡ 921 3.1 247 6.1 14.0 9.3
(n = 18) (785–1068) (-2.3–7.4) (183–324) (3–12) (12–16) (5–15)
Not Orally
Available§ 992 -2.5 341 10.6 14.6 13.5
(n = 26) (665–1269) (-7.2–2.3) (148–513) (2–17) (9–20) (3–29)
All Oral
344 2.3 78 1.8 5.5 5.4Drugs¶
(n = 1193) (200–475) (-0.8–5.2) (22–134) (0–3) (2–9) (1–10)
∗Numbers are mean values ± standard deviation, with the 10–90% range given in parentheses.
MW (molecular weight), PSA (polar surface area), HBD/A (hydrogen bond donor/acceptor), NRB
(number of rotatable bonds). Properties were calculated using ChemAxon Software Calculator plug-
ins (Marvin 6.0, 2013). P values represent the probability that the average property value for the
MC set in question differs from the average value for all oral drugs, and were calculated using
classical (non-paired) t-tests after establishing sample normality using the Anderson-Darling test.
†MC Drugs include all compounds in the CHEMBL Database that were listed as approved drugs
and that have a macrocyclic structure, plus a small number of additional compounds identified from
web-based sources. ‡The subset of MC Drugs that can be administered orally with the exception of
Nystatin which, though administered orally to treat GI tract fungal infections, is not systemically
absorbed (Melkoumov et al., 2013). §The subset of MC Drugs that cannot be administered orally.
¶ Values from Vieth et al. (Vieth et al., 2004)
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set MCs into large and small revealed significant differences in the properties, with
the small MCs occupying a property space more like the values seen for conventional
oral drugs — and closer to the RO5 criteria. The large MCs had values similar to the
orally available MC drugs; both of those sets have averages of more than double the
number of HBA and rotatable bonds, and more than triple the polar surface area and
number of HBD, compared to the conventional oral drugs. To help visualize these
differences Figure 2·5 depicts a spatial plot of the properties of molecular weight, polar
surface area, and number of rotatable bonds for each of the compound sets, as found
in Table 2.2. In this visual aid the chemical space occupied by the small MCs is almost
completely within the RO5/Veber’s rules space, and substantially overlaps with the
oral drug space. Looking at the three properties shown in Figure 2·5 demonstrates the
need to consider an alternate set of criteria when dealing with large MC compounds
as potential drugs. The only commonality throughout the compound sets was that of
average cLogP, which tended to be a similar range, except for the non-orally available
MC drugs. This analysis confirmed the hypothesis that the large MCs of the test set,
and the approved MC drugs, occupy a region of chemical space that is separate and
distinct from that of conventional oral drugs.
2.4 MC Characteristics and Binding Interactions
2.4.1 Binding Topology
Inspection of the structures for the MC-protein complexes in the test set revealed
that the MCs tended to adopt one of three general geometries for binding with the
protein: “face-on,” “edge-on,” or “compact.” Examples of the three binding modes
can be seen the sample structures shown in Figure 2·6. The face-on binding mode
describes compounds that lie flat along the surface of a protein, spread out over a
large area, occurring on regions of the protein that are themselves somewhat flat or
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Figure 2·5: Conventional drugs and MC drugs occupy distinct regions of chemical
space. The spheroids depicted are approximate representations of the 10th–90th
percentile ranges for values of MW, PSA, and NRB for the test set large MCs
(orange) and small MCs (blue), the 18 oral MC drugs (green), the 26 non-oral
MC drugs (purple), and the 1193 oral drugs from from Vieth (Vieth et al., 2004)
(gray). All values were taken from Table 2.2. The “X” symbol within each spheroid
marks the average values for the corresponding compound class, with the dashed
line showing the projection of those mean values on the 2D plot floor of MW vs.
NRB . The transparent box delineates the value ranges for Lipinski’s RO5 (MW ≤
500 Da) and Veber’s Rules (PSA ≤ 140 A˚2, NRB ≤ 10).
only have a shallow concavity These MCs sometimes even contour over regions that
are convex. The edge-on binding mode describes the MCs that bind along a groove
or cleft in the protein surface using only one side of the of the ring, such that the
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opposite side projects away from the protein surface, towards the solvent. The third
binding mode, compact, describes MCs that bind in a deep cleft or cavity and adopt
a more globular conformation, sometimes folding back on themselves. Interestingly,
the large MCs are split almost evenly between face-on and edge-on, while most of
the small MCs adopt the compact binding mode. The face-on binders also tended to
have large or long substituents that stretched out across the surface of the protein,
accessing deeper pockets or grooves adjacent to the site of the scaffold binding. For
the edge-on binders, substituent atoms extending from the ring also bind in the cleft,
while those atoms on the solvent-exposed side can extend out further into the solvent
or make some contact with protein surfaces outside of the cleft. Images of all the MCs
illustrating their binding mode are shown in Figures A·2 and A·3 found in Appendix
A.
A notable feature of the edge-on binders is that the biological role of most of
those MCs is to serve as a linker that facilitates the binding of two proteins together,
inhibiting the protein’s normal function. First the MC binds to one protein, then
that MC-protein complex goes on to bind to a second protein, which can either be
a monomer or hetero-multimer. The MC is located at the interface of the protein-
protein binding, interacting with both of the proteins. For these secondary complexes,
association of the two proteins does not take place unless the MC is present and it is
upon this secondary binding that the target pathway is inhibited (Liu et al., 1991).
Complexes of the test set that display this activity consist of only the MC and the
first binding protein, and include FK506/FKBP and CsA/cyclophilin, which both
bind calcineurin (Griffith et al., 1995; Jin and Harrison, 2002); and rapamycin/FKBP,
whose second protein complex partner is mTOR (Choi et al., 1996).
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Figure 2·6: MC binding configurations. A. Side-on binding mode, exemplified
by CsA bound to cyclophillin. B. Face-on binding mode, exemplified by PTX-2
bound to actin. C. Compact binding mode, exemplified by bc2 bound to HSP90.
Upper panels show the conformation of the ligand (blue) bound to its protein target
(wheat). The bottom two rows depict corresponding surface representations of the
MC ligands, viewed looking top down into the binding site and rotated to a low
angle side view. Ligand atoms are colored by amount of surface area they bury on
protein binding: red, ≥90% buried; orange, 50-90% buried; gold, 25-50% buried;
white, <25% buried. Corresponding ligand and protein abbreviations can be found
in Table 2.1.
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2.4.2 Methods for Analyzing MC Binding
In order to investigate the binding characteristics of the MCs it was necessary to define
which atoms of the compounds were interacting with the binding site of the protein.
This interaction was assessed in two ways: (1) the change in solvent accessible surface
area (SASA) and (2) a determination of atoms that come within contact distance.
The SASA was determined using methods based on Lee and Richards (Lee and
Richards, 1971), with scripts adapted from SASA calculations done on DNA by Li-
panov and colleagues (Lipanov et al., 1989). This method takes the van der Waals
radius of each atom and adds the radius of a spherical probe meant to represent
the solvent molecule. The exposed surface of this new, larger sphere is determined
and then summed for all the atoms in the molecule, resulting the in total solvent
accessible surface area. For our analysis the radius of water was used as the probe
(r=1.4 A˚), and the SASA was calculated for the whole MC, as well as each component
atom individually. For the individual MC atom analysis only those atoms burying ≥
5 A˚2 were considered, in order to exclude internal atoms that would likely not be able
to interact with the protein. ∆SASA values for the MC binding were calculated by
taking the difference of the MC SASA in isolation and the MC SASA when it was a
part of the bound complex. MC atoms found to experience a reduction of ≥5 A˚2 in
SASA are referred to in the following sections as buried atoms.
The contact atoms were defined as those atoms of the ligand that, in the complex,
were within 4.5 A˚ of any atom on the protein. This distance threshold is derived from
a study of non-bonded contact distances for the elements C, N, O, F, P, S, Cl, Br, and
I in X-ray crystal structures (Rowland and Taylor, 1996). For our study, this value
is meant to identify atoms that are close enough to the protein surface that they are
likely to interact with protein atoms. These ligand atoms do not necessarily make a
significant contribution to binding energy, but can at least influence or be influenced
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by the local environment of the protein surface.
2.4.3 Characteristics of the MC Binding Interface
Size of the Binding Interface
The size and location of the binding interface for both the large and small MCs was
determined using the ∆SASA calculations described above in Section 2.4.2. The
large MCs buried an average of 630 ± 116 A˚2 of surface area upon binding, which
corresponds to an average of 57 ± 8% of the large MC total surface area. This value
is fairly uniform considering the size range of the large MCs (673–1291 Da.) and is
only slightly dependent on compound size. The large MCs bury about double the
SA of a conventional drug, 300 ± 130 A˚2 (Jorgensen, 2004) and approach the average
800 ± 200 A˚2 SASA buried per protein at a typical PPI interface (Conte et al., 1999).
In contrast, the small MCs bury a fairly uniform 82 ± 4% of their SASA, which is
very similar to the value of 80 ± 13% buried SA found by Luque and Freire for small
ligands (Luque and Freire, 2000). The actual amount of SASA buried by small MCs
ranges from 377–621, which reflects the varied sizes of the small MCs (Figure 2·7A).
The values of buried SASA for the proteins of the complex can be seen in Table A.2
of Appendix A.
The values for the binding interface surface area correspond visually to the topo-
logical categories observed for the MCs (Sec. 2.4.1). The large MCs bury a little over
half of their SASA by either a face-on interaction, where one whole face of the MC
closely associates with the protein surface, or by the edge-on interaction, where about
half of the ring scaffold is buried. The ~80% buried surface value for small MCs is
a reflection of the compact conformations they adopt when bound deep in a cleft or
pocket. These differences in binding mode observed between large and small MCs
highlight the need to treat the two categories of MC independently when considering
a MC compound for a target. Because the small MCs tend to bind in more classically
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Figure 2·7: The protein-MC binding interface. A. The relationship between total
and buried SASA for large (circles) and small (triangles) MCs. The dotted line
corresponds to 100% MC SASA burial and the solid line is an arbitrary interpolation
of the data. The small MCs bury ~80% of their SASA upon binding, while the large
MCs bury a roughly uniform 630±150 A˚2. B. Comparison of the ratio of polar and
non-polar buried atoms versus all atoms of the MC.
shaped pockets, and in modes resembling those of traditional drug molecules, it is
possible to consider them as candidates for conventional protein targets, whereas the
large MCs are clearly less suited for such situations.
Distribution of Polar/Non-polar Atoms
It has been suggested that the structure of larger natural product MCs is such that
functional sub-domains exist, arranged so that there is a contiguous non-polar binding
region, balanced by a polar composition of the rest of the ring (Wessjohann et al.,
2005; Driggers et al., 2008). It is thought that this arrangement is the source of a
MCs ability to maintain good pharmacokinetics even at larger sizes, where the polar
region serves as a “modulator” domain, which can be changed to satisfy solvation
and absorption issues while the binding region, and its target affinity, remains the
same. To investigate this hypothesis we analyzed the non-polar/polar distribution of
the buried MC atoms, which we considered to be the binding region of the MC. On
average, for the large MCs the binding regions contained 73 ± 8 % non-polar atoms
(i.e. C, S, or Cl) and 27 ± 8 % polar atoms (N or O), which is almost the same as the
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71/29 ± 7 % non-polar/polar atom distribution of the entire MC structure (Figure
2·7B). The observation that the binding region of the MCs were not any more or less
polar than the rest of the molecule argues against the existence of polar and non-
polar sub-domains as an important feature of MC binding. These results are not an
artifact of averaging; examined individually, the MC compounds exhibit binding site
atom distributions fairly close to the ratio for their total atoms, which can be seen in
Figure A·1 of Appendix A.
This analysis was repeated for the corresponding surface areas of the MC binding
regions and for the MC 4.5 A˚ contact atoms, resulting in ratios of 76/24 ± 9 % and
73/27 ± 7 %, respectively. The similarity of the surface area ratio to the atom count
ratio validates the use of the number of atoms as a reasonable metric for the discussion
of polarity distribution, and that an atom counted in the binding site presents a
corresponding amount of surface area. The similarity of the atom distribution for
the 4.5 A˚ contact atoms to the overall non-polar/polar ratios further supports the
idea that polarity-based domains do not dictate which regions of the MC will make
contact with atoms in the protein binding site.
How the Different MC Regions Interact with their Target Protein
Visual inspection of the protein-MC complexes during the investigation of polarity-
based binding domains suggested that the different MC regions tended towards dif-
ferent levels of interaction in protein binding. We were interested to know if this
cursory observation of varying participation in binding was real and if so, what struc-
tural insight could be gained from assessing these regional binding characteristics. By
“regions” I refer here not to “sub-domains” as proposed by Driggers et al. (2008) and
Wessjohann et al. (2005), but rather to the ring, peripheral, and substituent regions
that were defined in Section 2.3.2. For large MCs, analysis by region showed the
substituents buried the greatest average amount of atoms (and SA) for large MCs,
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accounting for 55 ± 17% of the total amount of atoms buried; the remaining buried
atoms were split roughly equally between ring and peripheral atoms, with about 20%
and 25%, respectively (Figure 2·8 A). We were particularly interested in the contri-
bution by peripheral atoms, considering that they are the least numerous regional
atom type (Figure 2·4 A). Normalizing for the populations of atoms in the different
regions shows that, when present, the peripheral atoms are very likely to be involved
in the binding region, with 72 ± 17% of peripheral atoms buried (Figure 2·8 B). In
contrast, only about half of substituent atoms and a quarter of ring atoms are buried
for large MCs. This finding suggests that even though the chemistry and position of
peripheral atoms are often not the focus when creating linkers to cyclize acyclic leads,
or when developing substituents, they should be carefully considered during any MC
design process. The propensity of peripheral atoms to appear in the portions of MCs
that directly interact with the protein means they have the potential to disrupt or
weaken target binding if their chemistry is antithetical to regions of that binding site.
Separate analysis of the small MCs resulted in a different balance of regional
participation in binding. The binding sites of the small MCs are made up of a similar
proportion of peripheral atoms (22%) to the large MCs, but an even split by ring and
substituent atoms of 39% each. These difference in regional balance are not surprising
given the structural composition and the observed binding geometries: the large MCs
have at least one large substituent and more substituent atoms overall, and these
atoms tend to be used in the binding interface. In contrast, the small MCs are more
deeply buried in the protein, resulting in a greater number of ring atoms buried.
Another potentially important design implication is seen in the regional distribu-
tion of the 4.5 A˚ contact atoms, Figure 2·8 C. For large MCs 74 ± 11% of all ring
atoms are in contact range with the protein surface. So, although ring atoms may not
be as deeply buried in the binding interface (and therefore more likely to contribute
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Figure 2·8: Analysis of binding by MC region. A. Contributions of each region
to the total buried surface area for the MCs. B. Percentage of each region’s atoms
that are buried. C. Percentage of each region’s atoms that are within the 4.5 A˚
contact distance. D. The average polar/non-polar ratio for the buried atoms of
each region.
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appreciably to binding energies), they still have the potential to influence and be
influenced by the local environment. This is most clearly seen with face-on binding
compounds such as pectenotoxin (Figure 2·6 A) where large portions of the MC lie
close to the protein surface but do not fit into grooves, or are on the outer edge of
the ring. It would therefore be unfavorable for a design campaign to focus only on
optimization of the deeper binding components, treating the remainder of the com-
pound as simple linkers, as this could result in neighboring functional groups clashing
(chemically or sterically) with the environment just outside the primary binding in-
terface. This point is explicitly made only because of the many design strategies,
covered thoroughly in reviews on MC leads and clinical candidates (Giordanetto and
Kihlberg, 2014; Marsault and Peterson, 2011; Mallinson and Collins, 2012), where
emphasis is placed on optimization of a small portion of a MC for target affinity
while the remainder of the molecule is a linker being used to cyclize a small acyclic
lead. In some cases the connecting portion of the MC is planned into the structure
from the beginning but only to serve as a region available for later modification while
optimizing ADME properties. We feel that true potential for future MC drugs will be
derived from taking advantage of their size and shape in ways that are not possible
in smaller drugs or large acyclic compounds.
Analysis of the physicochemical composition of the buried atoms by MC region
revealed additional interesting features. Figure 2·8 D shows the percentage of polar
versus non-polar buried atoms for each of the three MC regions, compared to that for
the entire binding region of the MC. It can be seen that for substituent atoms, the
average polar/non-polar ratio is similar to that for the overall compound. In contrast
the ring atoms involved in protein contact are largely non-polar, while peripheral
atoms are much more likely to be polar. In fact, the buried ring atoms were 100%
non-polar for seven of the large MCs, and the peripheral atoms were 100% polar in
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one case. This result was surprising considering the similarity of the overall binding
region composition to that of the entire MC. Similar regional values were found for
the small MCs (see Appendix A). In light of these regional differences, the similarity
of the total buried site to the overall balance of atom polarity emphasizes the need
to consider all parts of a MC during the design process.
In summary, the regional analysis shows that, for the natural product MCs of
the test set, the substituents account for around half of the binding atoms, with
the remainder split roughly equally between the ring and peripheral atoms, which
is disproportionate for peripheral atoms relative to their representation in the total
structure. The substituent atoms in the binding site were found to match the polar
composition of the entire MC, but the ring atoms tend to comprise significantly
more non-polar atoms (90%). Additionally, when peripheral atoms are present in
the structure, they are highly likely to be included in the binding site and to be
predominantly polar. All of this information taken together (along with the binding
mode analysis) highlights the importance of ring and peripheral atoms in MC design.
Substituents of the MC are still important for binding to classic proteins pockets
and clefts, which makes them more likely to have a large contribution to the binding
energy. However, careful consideration should be given to ring and peripheral atoms
as they could play an important role in binding affinity and may also be useful in
target specificity.
2.5 Analysis of the Proteins that Bind MCs
A major factor in the recent interest in MC compounds for drug discovery relates
to their potential for binding protein targets previously considered out-of-reach using
conventional drug compounds (Section 1.1.2). We therefore were interested to know
whether the MC binding sites on the proteins in the test set contained any measur-
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able differences from binding sites for conventional drug-like ligands. This was done
by identifying binding site hot spots (see Section 1.2.1) using the FTMap fragment
mapping algorithm (detailed in Section 1.2.2) and comparing the results from the
test set to those obtained by mapping a representative set of proteins that bind tra-
ditional drug-like ligands. In addition to contributing insights for compound design,
data collected on the size, number, population, and distribution of hot spots could
provide a useful tool for identification of proteins suitable for targeting with natural
product inspired MCs.
2.5.1 Creation of the “Traditional” Compounds Set
The comparison set of conventional drug and drug-like ligands was compiled starting
from the structures in the Astex diverse (AD) set (Hartshorn et al., 2007). These
were supplemented with structures from the EMBL-EBI index of approved drugs
(DrugPort, 2012) to ensure a large and diverse sample size. As with the test MC test,
only inhibitor compounds were selected from the traditional drug sets; a cut-off of
IC50 ≤ 1 µM or KD ≤ 100 nM was used. Only one protein was used from each family,
to minimize bias. The AD set was originally created using strict criteria for the quality
of the structures, but those from the DrugPort index had to be assessed for acceptable
values for resolution, structure factors, and for the presence of artifacts from crystal
contacts. It should be noted that the AD set was not limited to complexes containing
approved drugs, but simply compounds “that are likely to be drug-like” (Hartshorn
et al., 2007), which passed filters for structure and physicochemical composition. The
final comparator set included a total of 24 complexes, with 12 from the AD set, 10
from the DrugPort index, and two that appeared in both sets. A list of the final set
of complexes can be seen in Table 2.3.
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Table 2.3: Complexes in the comparator set.
Ligand Protein PDB ID
Astex Diverse Set
Tomudex Thymidylate Synthase 1hvy
JE-2147 HIV-1 Protease 1kzk
BCX-1812 Neuraminidase A 1l7f
Compound 4 Thrombin 1oyt
Indirubin-3’-monoxime GSK-3 1q41
Resveratrol Quinone Reductase 2 1sg0
Compound 2 Dihydrofolate Reductase 1s3v
IDD552 Aldose Reductase 1t40
Compound 1 Fatty acid-binding Protein 1tow
TPI Thymidine Phosphorylase 1uou
Compound 59 NS5B Polymerase 1yvf
Compound 11 HSP90 2bsm
EMBL-EBI
Zanamivir Neuraminidase 1a4g
Tranexamic Acid Plasminogen 1ceb
Lovastatin LFA-1 (CD11A) 1cqp
Trifluoperazine Calmodulin 1ctr
Sitagliptin Dipeptidyl Peptidase IV 1x70
Aliskiren Renin 2v0z
Trimethoprim Dihydrofolate Reductase 2w3a
Indomethacin Prostaglandin Reductase 2 2zb8
Miglitol Maltase-Glucoamylase 3l4w
Galantamine Acetylcholinesterase 4ey6
Both Sets
Fluvastatin HMG-CoA reductase 1hwi
Tadalafil Phosphodiesterase 5A 1xoz
2.5.2 Development of “Bubble Mapping” Method for Site-Restricted
Mapping
To investigate the binding sites on the test set and comparator set proteins, a slightly
modified version of the FTMap (Brenke et al., 2009) method was developed to nor-
malize the areas being compared. This allowed for direct comparison of hot spot
population and distribution across different proteins. In this method, initial mapping
was restricted to a sphere, or “bubble,” of radius 10 A˚ centered on the ligand binding
site, as determined by the geometric center of each ligand; this radius was chosen to
accommodate even the largest MC ligand in our set. During the energy minimiza-
tion step the probes were allowed to move outside the sphere to ensure the true hot
54
spots were found. This so-called “bubble mapping” was performed on the protein
from each complex with the ligands and all water molecules removed. Only FTMap
consensus sites (CS) with a population ≥5 were retained (see Section 1.2.2 for details
on FTMap algorithm). An example of a typical result of the binding site analysis
using the restrictive bubble can be seen in Figure 2·9.
Figure 2·9: FTMap “bubble map” analysis of MC binding sites. Representative
result of the restricted mapping analysis, shown for PTX2 (magenta) binding to
actin (wheat). Probes were restricted to a 10 A˚ sphere centered on the ligand, shown
here as the transparent gray surface. Consensus sites are displayed as colored sticks
with small spheres at their geometric centers.
Binding sites for biologically relevant cofactors located away from the ligand site
are likely to be energetically favorable for protein binding and could cause probes
to be siphoned off to hot spots that would normally be occupied by that cofactor
during ligand binding. Therefore, all complexes with biologically relevant cofactors
co-crystalized were mapped with the cofactor present as part of the receptor struc-
ture. The comparator set contained six complexes with biologically relevant cofactors
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present; the cofactors were ADP, dUMP, FAD, and NADP. The actin complexes in
the MC set were all mapped with ATP present. For the case of the actin–latrunculin
B (LAB) complex, the protein was additionally co-crystallized with PTX present, so
the complex was mapped with that MC as part of the receptor as well.
2.5.3 Hot Spot Distribution at the Ligand Binding Sites
For all cases in the test and comparator set, multiple binding energy hot spots were
identified, illustrated in Figure 2·9 on the example case of PTX-2 binding to actin.
In the actin–PTX-2 example many of the CSs occupy regions of the binding site that
overlap with a majority of the MC; these include the highest ranking CSs, which are
those predicted to be most energetically important (Brenke et al., 2009). Other CSs in
nearby surface regions indicate areas with the potential to be energetically favorable
for ligand binding, but that are not exploited by the particular ligand present in
that complex (Hall et al., 2012b). The hot spot distance and population values were
calculated from the CSs alone, without regard to MC use of the hot spot in that
experimental complex, to reflect the intrinsic properties of the binding site. The
results from mapping of all of the test set MC binding sites, as well as those of the
comparator set of traditionally drug-like ligands, are compiled in Table 2.4. Results
from the individual complexes can be seen in Appendix Table A.5. Separate analysis
of small and large test set MC binding proteins revealed that small MC binding sites,
in most respects, resembled the binding sites in the comparator set rather than those
for the large MCs. Our findings regarding the characteristics of the protein binding
sites will therefore be discussed mainly as a comparison between the large MC and
comparator set proteins. The average number of total hot spots contained in the
binding sites for both the large MC and comparator ligand set were similar, allowing
for a direct and unweighted comparison.
When using FTMap, the distance of secondary CSs from the top ranked CS is used
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to determine the druggability of the target as well as to help define the direction and
extent of the binding site (Hall et al., 2012b). Using these secondary CSs, we wanted
to find out if the larger size and diffuse binding modes of large MC ligands were re-
flected in the hot spot distribution on their protein binding partners. A measurement
of the distance between the two CSs that define the furthest extent of the binding
site showed that binding sites for large MCs were about 15% larger than those for
conventional druglike ligands, corresponding to a difference in size along the longest
dimension of the binding site of about 2.5 A˚. The average separation of all hot spots
was also greater for the large MC binding sites (by about 1 A˚), but the separation
of the top two ranked hot spots was particularly greater, with an average distance
of 10.6 A˚ versus only 7.5 A˚ for the conventional ligand binding sites. In the case of
one of the large MCs the separation of top ranked CSs was nearly 18 A˚, and multiple
other large MC sites had separation above 11 A˚. In contrast, in over 80% of cases the
top two ranked CSs for the traditional set were within 9 A˚ of each other. Though
the two highest ranked CSs were not always separated by very large distances for the
large MC binding sites, the smallest separation was 7.86 A˚, slightly greater than the
average top ranked CS distance for the traditional ligand set.
The notable differences in hot spot topology could be useful in the identification
of protein targets for MCs, whether they are novel targets or those that have proven
difficult for development of conventional drug-like ligands with suitable inhibition
affinity. Because of the use of focused mapping here, these trends would be more
useful for proteins where the binding region is known. This stipulation does not
preclude application of the methods to novel targets, but some information about the
desired site for inhibition would be needed. For the known but difficult targets, a hot
spot distribution similar to that found for the large MC binding sites could indicate
that conventional druglike compounds display weak binding because they are not able
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to take full advantage of the binding site hot spots. A larger MC compound might
make better use of the wider spaced hot spots, without incurring the entropic cost
associated with binding a similarly sized acyclic molecule. This argument would be
especially strong for those cases where weak binders occupy one high ranking CS,
but don’t extend far enough to access any nearby CSs, or only access a very weak
secondary CS (discussed further below).
2.5.4 Ligand Occupancy of Hotspots
In addition to assessing trends in the intrinsic features of the binding site, we were
interested to see if the MC ligands made use of the hot spots differently than did
the conventional druglike ligands. A set of criteria was created to identify whether a
given ligand occupied a hot spot—meaning the ligand overlapped with the CS probes
such that it is reasonable to assume the ligand atoms would make use of the favorable
energy available through interaction at that site. First, a distance cutoff was used
to identify instances in which the geometric center of the probe cluster was within
2 A˚ of any non-hydrogen ligand atom. However, this condition alone was found to
be too permissive; upon visual inspection of sample cases it sometimes indicated
occupation of some CSs that were intuitively unreasonable. The additional criterion
of a minimum of 25% of the CS probe atoms being within 1.25 A˚ of a ligand atom
resolved those cases where proximity to the geometric center of the CS alone was not
a sufficient predictor. Figure 2·10 A depicts an example of occupied/unoccupied hot
spots, illustrated by scyptolin binding to pancreatic elastase.
The results of the hot spot occupancy analysis showed that large MCs exploit the
hot spots of their binding sites differently than the druglike ligand set. The large
MCs occupied an average of 5.2 hot spots, in contrast to the comparator set which,
on average, only occupied 3.6 hot spots (corresponding to 66% versus 45% of total
hot spots, respectively). When broken down by ranked CS, as illustrated in Figure
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Figure 2·10: Ligand occupancy of hot spots. A. Illustration of hot spot occupation
for scyptolin (pink) bound to pancreatic elastase (wheat). Green coloration of CS
indicates occupation criteria met and red indicates not met. B. Number of CSs
occupied by ligands from the MC test set (blue) or the drug-like ligand comparator
set (red). The plot shows the total number of probes that the ligands overlap with,
starting from the most highly-populated of the occupied CSs (ranked number 1) to
the least populated (highest CS number), averaged over the entire set of complexes.
The average number of CSs occupied is 5.2 for the MC ligands compared to 3.6 for
the drug-like ligands (see dashed lines and Table 2.4).
2·10B, the number of total probe clusters overlapped by the large MCs is seen to
plateau more slowly than for the conventional compounds. Interestingly, the small
MCs have an occupation trend in between that observed for the large MCs and the
comparator set; they were more similar to the large MCs even though they more
closely resembled the comparator set for all other properties investigated.
2.5.5 Global Mapping and Classical Druggability Analysis
Finally, the test set proteins were assessed for druggability with respect to conven-
tional small ligands. We wanted to determine whether the MC binding sites might
still display characteristics that would suggest they can bind druglike ligands, or
if those sites are actually uniquely targeted by MCs. (See section 1.2.2 for details
on druggability prediction and on the FTMap algorithm.) The standard FTMap
protocol, implemented with the FTMap server (ftmap.bu.edu), was used to globally
map crystal structures of the unbound versions of the proteins in the test set MC
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complexes. When present, biologically relevant cofactors were included, consistent
with the published FTMap druggability analysis (Brenke et al., 2009; Kozakov et al.,
2011). A full list of the unbound structures and details of the individaua mapping
results can be seen in Table A.6 of Appendix A. The only protein missing from
this global mapping analysis was PhoQ, because an unbound structure meeting the
quality criteria, and with the rdc binding site open, was not found in the PDB at
the time. Sites on the protein were considered druggable if they contained a CS of
>16 probe clusters plus at least one other CS of ≥5 probe clusters within 7 A˚ of the
first (Hall et al., 2012b; Hall et al., 2012a). Of the 15 MC binding sites investigated
nine were rated as not druggable, indicating that the majority of binding sites in the
test set would have a low expectation for binding a conventional ligand with druglike
affinity. The large proportion of MC sites rated as not druggable has implications for
the use of MCs as a way to expand the scope of proteins targeted by drug discovery
campaigns, as discussed below.
2.6 Lessons from the Binding Modes of Specific Complexes
Interaction Modes of MC Ligands with a Shared Target
There were multiple cases in our test set where structurally different MCs bound to
the same protein, providing an opportunity for comparison. These complexes afforded
insight into the influence of binding sites on ligand binding modes, by comparing the
extent to which different ligands adopted similar conformations to access the same
set of hot spots. The complexes in the test set that fall into this category are: actin
with Reidispongiolide A and Kabiramide C, chitinase with Argadin and Argifin, cy-
clophilin with CsA and Sanglifehrin A, FKBP with FK506 and Rapamycin/Sirolimus,
and Hsp90 with Radicicol, Pochoxime A, and the ansamycins Geldanamycin and
Macbecin. The relationship of multiple binders at the same protein site has previ-
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ously been extensively described for FKBP and for Hsp90 (Van Duyne et al., 1993;
Roe et al., 1999; Kitson and Moody, 2013), so here we will focus on actin, chitinase
and cyclophilin.
Reidispongiolide A (RgA) and Kabiramide C (KabC) both bind to actin at the
same surface site, the shallow depression and adjacent narrow cleft between subdo-
mains 1 and 3 (S1 and S3), where the actin-regulating protein gelosin binds (Alling-
ham et al., 2005; Klenchin et al., 2003; Sun et al., 1999). Both ligands have a structure
that takes advantage the dual features of the binding area. The first shared feature
is a large linear substituent, often referred to as the aliphatic tail, that extends into
the narrow S1/S3 cleft, burying the majority of its surface area. The second feature
is a large ring (≥25 atoms) that adopts a face-on conformation (see Section 2.4.1
for discussion of MC topologies) in the shallow hydrophobic patch next to the cleft.
However, while the linear substituents of these two MCs are nearly identical, includ-
ing terminating in the N -methyl-vinyl-formamide (MVF) group, the composition of
the rings exhibit a lot of variation (Figure 2·1, page 32). Figure 2·11A shows that,
while the substituents bind in a nearly superimposable fashion along the cleft, the
large rings adopt distinct configurations, with only a small portion of the binding area
shared by both. It follows that the two MCs therefore utilize different hot spots to
achieve binding, which is borne out in the mapping results (Figure 2·11A). Though
the substituents of both ligands access hot spots located in the same three places
along the narrow cleft, the two MC rings occupy just a single common hot spot.
RgA additionally occupies a hot spot on the S1 side of the binding area while KabC
accesses three additional hot spots on the S3 side.
The variation in KabC and RgA scaffold binding highlights a possible means by
which MCs achieve binding sufficient to inhibit what would otherwise be considered an
“undruggable” target. The MC substituent tails are highly conserved (especially the
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MVF group), they share many of the same amino acid interactions along the S1/S3
cleft in actin (Allingham et al., 2005; Klenchin et al., 2003), and the strongest hot
spot is located in the cleft for both complexes. Given the conservation of substituent
structure and binding site, it is likely that the variation in the rings of these large
MCs means they are serving more of a structural support role in binding, ensuring the
aliphatic tail can bind along the cleft. Indeed it has been suggested that the ring binds
weakly first, as an anchor, then the long aliphatic tail to bind strongly in the cleft
(Klenchin et al., 2003). Although the MVF moiety has been shown to be essential for
strong binding of the MCs to actin, stable interaction of the ring is also correlated to
binding success (Allingham et al., 2005). The rings of RgA and KabC were shown
to occupy several lower ranking hot spots that, though less energetically important
individually, might collectively satisfy the threshold necessary for strong binding,
when combined with the substituent. Additionally, these large rings may be deriving
further stability on the relatively flat, hydrophobic surface from the conformational
restriction of the cyclic structure (Allingham et al., 2005). The difference in the
regional interactions of MCs binding actin is also reflected in our findings for the
contact atoms and buried atoms populations (see Section 2.4.2). The aliphatic tail
substituents bury 95% of atoms, whereas the rings bury less than 50% of atoms, even
though 80% of ring atoms are in contact range. This arrangement shows that even
though the ring portion of the MC does not fit deeply into a cleft a majority of the
ring atoms are arranged in a way that keeps them close to the protein surface.
The MCs argadin and argifin binding their shared protein target, chitinase, pro-
vides another example of varied exploitation of hot spots in the same binding site.
Like the actin binders discussed above, argadin and argifin make use of the hot
spots in different ways: both MCs contain a ≥10 atom long substituent terminat-
ing with a guanidine and carbonyl functionality (N -methylamide for argadin and
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Figure 2·11: Comparison of binding modes for distinct MCs binding to a common
target site. A. Reidispongiolide A (yellow) and Kabiramide C (green) bound to
actin (wheat). The locations of the FTMap CSs are shown as colored sticks. B.
Argadin (Green) and Argifin (yellow) bound to chitinase (wheat). Right panel is
a superposition of the two ligands, with the protein removed, to more clearly show
the head-to-tail relationship between their binding modes, and the overlap with
the FTMap CSs. C. Cyclosporin A (green) and Sangliferhrin A (yellow) bound to
cyclophilin (wheat). Lower right panel is a superposition of the two ligands, with
the protein removed, to more clearly show the relationship between their binding
modes, and the overlap with the FTMap CSs.
acyl for argifin), but the substituents are oriented towards different ends of the bind-
ing pocket (Figure 2·11B). The variation in hot spot occupancy continues for the MC
rings, with each ring located in the same general area of the binding site —where
the pocket widens— but they have very little overlap with each other. For argifin
the hot spots are accessed only by substituents, meaning the ring may serve mostly
as a scaffold to orient the substituents to positions >10A˚ from one another, while
argadin’s ring actually occupies multiple high ranking hot spots, making it likely to
play an active part in ligand binding.
The third example of two MCs that bind to a common site, cyclosporine A (CsA)
and sanglifehrin A (SfA) bound to cyclophilin (Figure 2·11C), presents an interesting
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variation. Both MCs adopt an edge-on binding mode, resulting in only about half
of the atoms oriented towards the binding site at all. The other half of each MC is
off of the protein surface, into the solvent, in order to subsequently interface with
a second protein. The locations of the MC ring segments in the binding site have
a lot of overlap, and occupy many of the same hot spots; however, the substituents
take advantage of different hot spots. Specifically, SfA has a large substituent fully
situated in a large, highly ranked (CS2) hot spot that CsA only tangentially contacts.
Therefore, even though the topology of the binding site restricts the size of the com-
pound and the orientation of the binding mode, the structures of the two MCs and
how they access the site are quite different.
2.7 Proposed Design Guidelines for Macrocyclic Drugs
It has been established that there is interest and promise in macrocyclic compounds as
a means of accessing difficult-to-drug proteins, thereby increasing the pool of potential
pharmaceutical targets (Section 1.1.2). Because of the myriad MC structures possible
with modern synthesis techniques, the potential for MCs to expand drug discovery
opportunities will depend, in part, on being able to identify beneficial compound
characteristics. It would be useful to know which features of MC structures are likely
to lead to good target binding and which contribute to favorable pharmacokinetics,
as both are necessary to create an effective drug. A starting point for collating such
important features of MCs is the molecular properties found in familiar guidelines
like Lipinski’s Rule of Five and Veber’s rules. The tentative guidelines we propose
for those properties commonly used to assess druglikeness are collected in Table 2.5,
and are based on the observed values for the 18 orally available approved MC drugs
(Appendix Table A.7). Although the values for our guidelines are derived from a small
set of compounds the set includes all known examples of orally available macrocyclic
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drugs, and those compounds display consistent properties that are distinct in many
ways from those observed for conventional drugs.
Table 2.5: Proposed physicochemical guidelines for the design of synthetic MCs
Property Conventional Drugs Oral MC Drugs Parenteral MC Drugs
MW ≤ 500∗ 600–1200 600–1300
clogP ≤ 5∗ -2–6 -7–2
PSA ≤140 A˚2∗∗ 180–320 A˚2 150–500 A˚2
Number of HBD ≤ 5∗ ≤12 ≤17
Number of HBA ≤ 10∗ 12–16 9–20
NRB ≤ 10∗∗ ≤15 ≤30
While the properties outlined in Table 2.5 are potentially helpful design parame-
ters when developing a synthetic MC drug or creating a MC compound library, they
still encompass a large amount of varied chemical space. We felt the lessons derived
from our analysis of MC compounds bound to their target proteins could provide
further design guidelines, including structural features likely to have pharmacological
benefits. The properties of the large MCs contained in our test set of protein-MC
complexes coincide closely with those of the oral MC drugs, supporting the notion
that analysis of the binding modes of the test set might return information relevant
to the design of orally available MC compounds. This analysis led us to identify a
number of structural features in the MCs that are common to these pharmacologically
active MCs.
(i) The oral MC drugs and the large MCs in our test set typically contain one
or two large substituents, often totaling 20–30 heavy atoms or more, plus sev-
eral much smaller substituents such as acetyl, methoxy or isobutyl groups. In
natural product MCs, the vast majority of substituent atoms, including small
peripheral groups attached to ring atoms, participate directly in contact with
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the protein. Thus, structural diversity in these regions is an important consider-
ation when designing MC libraries for drug discovery. Although only about one
in three ring atoms contacts the protein, collectively, these contribute ~25% of
the contact area. Moreover, ring, peripheral and substituent atoms that contact
the protein are equally likely to bind at a hot spot. Therefore, all of the regions
of the MC must be considered potentially important for achieving good binding
complementarity.
(ii) The disproportionate role in binding played by single heavy atom substituents
attached to the ring suggests that achieving an appropriate number and diver-
sity of such peripheral groups is important for good protein binding activity.
Mimicking natural product MCs by including multiple polar atoms in these
peripheral positions also provides a means to ensure adequate PSA, which is
critical for good aqueous solubility and thus for pharmaceutical utility.
(iii) The regions of the MC that interact with the protein target, and the MC
structure as a whole, have a druglike physicochemical balance of one polar (O
or N) atom per two or three non-polar (C, S, Cl) atoms. Consequently, the clogP
for oral MC drugs is similar to that for conventional drugs, whereas absolute
PSA scales with MW and is much higher.
(iv) Whether a large MC adopts an edge-on or a face-on binding mode seems
to be dictated by the topology of the protein surface. However, different MC
structures can interact at a given binding site in otherwise quite distinct ways
by exploiting different subsets of the available binding energy hot spots. The
face-on binders often bind such that a large—in some cases, almost drug-sized—
substituent can access a substantial neighboring pocket or cleft. The edge-on
binders typically display a bound conformation in which the ring is flattened and
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elongated, such that even substituents attached to the solvent-exposed edge of
the ring can reach to make extensive contact with the protein (Fig. 5c). Thus,
even for edge-on binders, the substituents are typically not restricted to a single
edge of the MC ring. These findings argue that a diverse, general-purpose MC
library with large and small substituents distributed around the ring might have
utility across a wide range of different protein binding site topologies.
(v) A common feature among the oral MC drugs and the MC test set is a sub-
stantial degree of unsaturation in the ring, owing to alkene or amide bonds or
to crosslinks or externally fused small rings. Unlike rotatable bonds in general,
single bonds within an MC ring do not substantially mitigate against oral avail-
ability. Nevertheless, the relatively high degree of unsaturation observed for
these MCs suggests that substantial rigidification of the MC ring is a feature of
pharmaceutically relevant MC chemotypes.
The MC structural features described above are summarized in Table 2.6, which,
together with the property ranges in Table 2.5, we tentatively propose as a set of
design guidelines for synthetic MCs intended as pharmaceutically useful binders or
inhibitors of protein drug targets. These guidelines must be considered as provisional,
requiring validation and further refinement based on prospective experimental tests.
Nonetheless, the available evidence supports the notion that compounds conforming
to these properties represent a useful class for the discovery of pharmacologically
active synthetic MCs.
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Table 2.6: Proposed structural guidelines for the design of synthetic MC libraries
Property Observed Rangea
Ring size (R) 14–38
Number of substituents 4.4 (3-8)
Large substituents (≥5 HA)b 1.9 (1-3)
Small substituents (2-4 HA)b 2.4 (1-6)
Proportion of HA that are in substituents 47% (40-59%)
Number of peripheral groups 5–12
Polar/nonpolar balance, substituents ∼30/70
Polar/nonpolar balance, Peripheral groups ∼60/40
Degrees of unsaturation in ring ∼ 0.4R – 4(±3)
N:O ratio 0.25:1 (0-0.4:1)
Chiral centers 15 (9-18)
aMean (10-90% range). bHA (nonhydrogen atoms). Values for the individual MCs
can be found in Appendix Table A.8.
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Chapter 3
Design of a NEMO Inhibitor
The following chapter covers the work I did as part of an interdisciplinary multi-lab
collaboration towards the identification of an inhibitor of the NEMO/IKKβ com-
plex. The team consisted of the Whitty group (biochemical analysis), the Vajda
group (computational analysis), the Allen group (crystallography and structure), the
Porco group (organic synthesis) and the Gilmore group (NEMO biology). Although
a NEMO/IKKβ inhibitor was not identified during my time on the project, compu-
tational lead design methods, macrocycle synthesis methods, and inhibitor screen-
ing methods were developed. Additionally this NEMO collaboration work led to
characterization of NEMO structure and organization, further understanding of IKK
complex formation, and information about key regions in the NEMO/IKKβ binding
site.
3.1 Introduction
The increased attention on PPI targets following the slow down in new pharmaceutical
successes (Section 1.1.2) has made proteins like the IKK complex more appealing—
proteins with known biology of therapeutic interest but difficult to inhibit. Because of
its biological relevance, the NEMO/IKK complex, and the NF-κB pathway in general,
has long been a target for pharmaceutical intervention. However, its complicated,
non-globular structure has made it difficult to develop a small molecule inhibitor
(Section 1.3). As discussed in Section 1.1.2, macrocycles have become a compound
class of increasing interest for targets with non-classical binding sites, such as PPI
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interfaces, making macrocyclic chemical space a logical region in which to seek a
solution to the difficulty of inhibiting NEMO.
There are multiple factors that led us to explore macrocyclic compounds for an
inhibitor of the IKK complex. In a crystal structure of the N-terminal domain of
NEMO complexed with IKK (Rushe et al., 2008) the binding site of the mostly
α-helical IKKβ NBD appears as a long, shallow cleft formed by the interface of
NEMO’s coiled coil structure (see Section 1.3.1 and Figure 1·6 for details on the
NEMO structure). This topology puts the NBD site somewhere in between the
narrow, deep pockets common to small drug targets, and the diffuse, often flat surfaces
of some of the most difficult PPI targets. Indeed it has been suggested, based on
successfully inhibited PPIs, that interfaces involving an α-helix are toward the more
tractable end of the difficulty spectrum for PPIs (Arkin and Whitty, 2009; Arkin
et al., 2014; Jochim and Arora, 2010; Azzarito et al., 2013). However, although
the number of cases where small molecule inhibitors have been identified for PPIs
is increasing, the number of those compounds with sufficient drug-like properties to
reach clinical trials is still limited. If α-helix mediated PPIs are predicated on helical
peptide strands binding, it is logical that the binding interface would be optimized
to take advantage of the residue spacing, resulting in hot spots spaced at least as far
apart as a helical turn (Arkin et al., 2014). An acyclic small molecule analog would
therefore need to have a long shape in order to fully engage multiple hot spots of
this type, a structure that is thought to reduce oral bioavailability (see Section 1.1.2).
Additionally it can be observed (in the crystal structure) that the two NBD binding
sites in the complex are non-identical, possibly a result of flexibility of the region. A
flexible binding site would pose another problem for traditional druglike compounds,
which depend on small, well-defined pockets. We therefore developed the hypothesis
that macrocyclic compounds, through their balance of flexibility and organization,
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could provide the multiple pharmacophores and larger spacing while maintaining the
stability needed to retain favorable binding and physicochemical properties.
Given the vast number of possible macrocycle structures, even when restricting the
main ring scaffold to an appropriate size to fit the NBD site, we needed a starting point
to create our virtual compound library. Ideally our basis for MC library design would
contain some pharmacophoric data in addition to the general spatial information
derived from standard global mapping results (e.g. minimum compound length). To
this end, we used a tool under development by the Vajda lab that looks for chemical
groups likely to be favorable for binding at particular hot spots by using recurring
patterns of functional moieties. The functional group clustering is further detailed in
Chapter 4, where I discuss my work on implementing an expansion of a the FTMap
probe set. Details on the design and composition of expanded probe set (used for
some mapping discussed in this chapter) can also be found in that chapter.
This chapter will cover the computational work I did towards the collaborative
effort of identifying an IKK complex inhibitor. The work regarding the use of the
expanded probe set (detailed in Chapter 4) was a preliminary application of a nascent
mapping augmentation developed by Brandon Zerbe. The main portion of this chap-
ter pertains to the work I did in close collaboration first with Dr. Aaron Beeler and
then Dr. Spandan Chennamadhavuni of the Center for Chemical Methodology and
Library Development (CMLD), who were the synthetic chemists in charge of MC
library synthesis. This work is as yet unpublished. As part of the NEMO project,
the focused mapping protocol I designed (Section 2.5.2) was modified and used to
identify NEMO hot spots outside the NBD. This work is described in the ACS paper
on the experimental and computational analysis of the PPI interface of the between
NEMO and IKKβ (Golden et al., 2013). The NEMO project is still ongoing, so this
chapter mainly describes the methodology developed toward synthetic library design.
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3.2 Initial Mapping of the IKK Complex
3.2.1 Hot Spots and Druggability of the NBD Site
Work on the NEMO project began with a druggability assessment of the hot spots
of NEMO44−111, performed using FTMap (see Section 1.2.2). Global mapping of
the X-ray crystal structure of the bound NEMO/IKKβ complex (3BRV) was carried
out using the 16 probe set and standard FTMap protocol. Both IKKβ chains were
removed prior to running the FTMap algorithm. Herein, results may be referred to
in terms of the “A side”/bent cleft or “C side”/open cleft, which correspond to the
side of NEMO where the “A” or “C” copy (referring to the crystallographic chain
identifier) of the IKKβ peptide bind, respectively. This is illustrated in Figure 3·1 A,
where the IKKβ A chain is shown in blue and the C chain in yellow. Global mapping
identified several consensus sites (CS) along each IKKβ binding cleft (Figure 3·1 B),
with CS1, CS2, and CS3 (colored cyan, magenta, and yellow for C side) residing in the
NEMO pocket where IKKβ residues Phe734, Leu737, Trp739, Trp741, and Leu742
bind. This result agrees with the established location of the NBD region (May et al.,
2002), with the addition that the mapping suggests Phe734 might also be important
to binding. Concerning the druggability of this site on NEMO, CS1 and CS2 satisfied
the FTMap population requirement for druggability (Section 1.2.3) but were slightly
further apart than the 7 A˚ usually accepted for a target to be considered druggable by
conventional methods. However, the two hot spots are still well within the distance
spanned by known macrocyclic inhibitors and it is therefore possible a MC could be
designed to access both hot spots.
Although the NBD site was successfully identified with global mapping of the
complex with the NEMO dimer-only, the presence of NBD binding sites on both
NEMO faces (see section 1.3) resulted in less populated secondary clusters on the A
side and weak clusters overall on the C side. The unusual dual-faced structure of
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Figure 3·1: The NBD interface and preliminary mapping of the NEMO protein.
NEMO chains are shown as surface representation in wheat; IKKβ chains shown as
cartoon depiction with critical residues shown as red sticks. A. The slight conforma-
tional differences at the NBD interface on the two faces of NEMO in the published
structure. The A side (blue IKKβ) NBD site is more narrow than the C side (yellow
IKKβ) in the region indicated by the orange arrows. B. Results of global mapping
of NEMO protein, A side, with FTMap. CS1 (cyan) and CS2 (magenta) occupy
the same region of the cleft as the critical IKKβ residues.
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NEMO creates a situation that is essentially like using the same amount of probes to
map two proteins instead of one, limiting the number of probes that will populate the
consensus sites on any one side. To attain more information about the site on each
face, each IKKβ peptide binding site was mapped individually by leaving the opposite
IKKβ chain in place, essentially blocking off probe access to that site. This masked
mapping approach was used for all later mapping analysis discussed throughout the
chapter.
3.2.2 Test of Expanded Probe Set to Identify Functional Group Leads
As a way to generate a starting point for macrocycle design NEMO44−111 was mapped
with the expanded probe set (EPS) described in Chapter 4, focusing on the NBD
region using a restrictive box (Figure 3·2A). This focused box mapping functions
similarly to the bubble mapping method described in section 2.5.2, where only those
probes that fall within the box after the rigid body docking move on to the mini-
mization step. The restrictive box encompassed the entire area around the NBD site
on NEMO, including all of the cleft around Trp741 and Lue742, and continuing past
Phe734 ~8 A˚ towards the N-terminus. The raw results of EPS mapping alone are a
number of large, densely clustered, and overlapping consensus sites, which are diffi-
cult to interpret for relevant information (Figure 3·2A). Therefore, an algorithm was
applied to the CS data that identifies the functional group substructures present in
each probe and then performs cluster analysis based on those functional groups (see
Chapter 4). A sample of the functional groups we were interested in are illustrated
in Figure 3·2B, where A indicates an arbitrary atom. This substructure approach
allowed for varying levels of functional group detail to be selected, e.g., we could
look for the prevalence of any aromatic group at a site or specifically a benzene ring.
Resulting clusters from the functional group analysis can be seen in Figure 3·2C.
It should be noted that at the time of its application to the NEMO project the
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Figure 3·2: Focused box mapping of NEMO with the EPS and resulting functional
group clustering. A. Results of mapping the binding site on NEMO with the EPS
(A side shown here). The wireframe box shown depicts the region used for restricted
mapping. B. A sample of the substructures used for the functional group clustering
analysis applied to EPS results. The ”A” in some structures indicate any atom
allowed at that site. C. Post clustering results. Groups passing the normalized
population criteria are shown as line structures. The red sticks are the three IKKβ
side chains, F734, W739, and W741.
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Figure 3·3: Examples of the substructures and possible substituents identified
from functional group clustering on the EPS mapping results. The CMLD was
provided with the general substructures as well as some more detailed moieties to
serve as a design starting point for functionalizing the MC scaffolds.
EPS and functional group clustering algorithm were in nascent stages and still under
development. Issues with how FTMap performs the minimization step as well as its
handling of hydrogen bonds meant that the results required a lot of user analysis
to parse out potentially useful functional group patterns. However, use of the EPS
mapping here was not for determination of a specific chemical group and its exact
orientation in space, but merely for generation of a set of lead structures for the
substituents of the MC scaffolds. To this end all we were looking for were general
group types that tended to appear frequently in the probe clusters and moieties
that seemed to best fit into the hot spots while adopting positions reasonable for
incorporation onto the planned MC scaffolds.
Once some initial substructures were identified from the clustering analysis they
were passed along to the CMLD for the next step in designing macrocyclic binders
of NEMO. A sample of substructures and suggested functional groups can be seen in
Figure 3·3. From these initial structures the CMLD generated possible substituents
for MC scaffolds that were synthetically accessible with CMLD methodology (exam-
ples provided in Figure 3·4). With reasonable MC scaffolds selected and starting
functionality identified for the substituents the CMLD could begin enumeration of
feasible permutations of virtual MCs.
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Figure 3·4: Examples of the scaffolds and substituents considered for early rounds
of virtual MC libraries. Z1, Z2 correspond to R group substitution positions seen
in the MC scaffolds.
3.3 Computational Triage and Refinement of Virtual Macrocycle Sets
3.3.1 Docking and Hot Spot Correlation for Sets <10000 Compounds
The large number of possible MC compounds generated by the CMLD meant that we
needed a way to prioritize synthetic efforts. We designed a triage process based on
how well the structures fit in the NBD cleft (overall size and shape), while being able
to access the known hot spots. If a compound fit along the binding cleft but did not
have any functionality near the hot spots, or if its substituents overlaid well with the
hot spots but the bulk of the structure was away from the protein, the binding would
very likely be energetically unfavorable. This ranking process could be applied both
to an initial library design used to test and select structures and functional groups,
as well as to a refined set of MCs targeted for synthesis. An overview of the workflow
for the triage of virtual MC sets (covered in detail below) can be seen in Figure 3·5.
To begin, theoretical molecule sets of two dimensional MC structures were de-
signed by the CMLD based on the methodology they developed for MC scaffold
synthesis and substitution. After the MCs were generated with Reactor (ChemAxon)
as two dimensional structures, the CMLD converted them to three dimensional, low
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Figure 3·5: A depiction of the process for designing and evaluating the virtual
MC compound sets.
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energy conformations with Molconverter, in MOL2 file format. For these initial 3D
structures, multiple low energy conformations were often provided for each compound.
Before the structures could be assessed for alignment with the hot spots it was nec-
essary to dock them to the binding site on NEMO, to generate relevant low energy
conformers in the presence of the protein. For each MC in a virtual set, 10 docked con-
formations were produced using AutoDock Vina (vina.scripps.edu (Trott and Olsen,
2010)). For docking, the structures were confined to the NBD site with a restric-
tive box defined around the site, similar in size and placement to the EPS mapping
box described above (Figure 3·2A). During the docking calculations the Autodock
Vina program allowed for rotation of substituent groups, but allowed for little to
no movement of ring atoms. All docked conformations of all MCs were then run
through an in-house program (developed by Dr. Dmitri Beglov) which evaluated the
overlap of each pose with the atoms of the consensus clusters generated by FTMap
(16 probe version), ranking them based on how well they overlapped with the hot
spots. The output of this program could be analyzed in terms of individual favor-
able conformations or the performance of a compound throughout all of its generated
conformations. Identifying the best individual conformation means ranking the en-
ergies from all poses of all molecules in the set, looking for the lowest overall energy.
Identifying the best compound means adding the energies of all the conformations
for a single compound to look for compounds that consistently adopted low energy
conformations.
The results of the virtual screening did require some manual intervention as a
post processing step before prioritized structures could be provided to the CMLD. To
ensure there were no artifacts from docking, the 50 top ranking poses were evaluated
visually for their fit in the NEMO cleft, and poses with large segments oriented
completely into the solvent space were removed. Such conformations were eliminated
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because even if the contacts in the binding site were favorable and coincided well
with the hot spots, the existence of large regions of solvent exposed atoms would
likely be energetically unfavorable. Poses of the same compound that were nearly
identical were also removed; these poses were a result of multiple initial conformations
received from CMLD converging to the same docked position. Additionally, docked
compounds that seemed to be making polar contacts with nitrogen atoms already
internally satisfied by backbone interactions were noted (since they may be falsely
high-ranking). As the virtual screening was performed independently for both sides
of the NEMO protein, we also noted those compounds that were highly ranked for
both sites, so long as they were similarly oriented along the clefts.
From the virtual screening results, the top 20 compound structures from each side
of NEMO were sent back to the CMLD, to be used in the design of the next set of
virtual library compounds. Trends in the top ranking MC structures and poses were
used to inform further rounds of virtual libraries of related compounds. Structural
features such as scaffolds that fit the NBD cleft better or repeatedly orient functional
groups advantageously would be investigated for further functionalization options.
Trends in which functional groups appeared in the top hits most often (with useful
orientation) were used in the generation of later rounds of virtual MC libraries. Once
refinement on the initial MC designs was done, the top compounds were used to select
synthetic target molecules. Again, Figure 3·5 shows an overview of the MC design
and evaluation process.
Results of Early MC Exploration and Set Enrichment
Following the earliest pilot MC sets used to develop and test docking and ranking
of compounds (see Fig. 3·4 for structure examples) we moved to larger scaffolds
with additional substituents. The smaller scaffolds and shorter substituents were
overlapping well the functional groups derived from EPS mapping, but were only
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Figure 3·6: An example of a compound from the pilot virtual MC sets. These com-
pounds were used to explore what types of scaffolds and substitution points would
best fit the NDB site on NEMO. A. The example compound (gray sticks) docked
into the NEMO A side cleft (wheat). Functional cluster results from EPS map-
ping used to generate this early compound are shown as lines. B. The compound
showing overlay with EPS results. C. Structure of the example compound.
minimally contacting the NBD site. An example of an early structure from these
smaller compounds can be seen in Figure 3·6. The first set of the larger MC structures
received from the CMLD was a small set of 240 compounds (340 total conformations).
The scaffold and top ranking structures from the prioritization process are shown in
Figure 3·7. Compounds 1–10 were found for the A side cleft, with 1–6 appearing
multiple times. Compounds 4, 6, 11–18 were found for the C side cleft, with 4, 11 and
16 appearing multiple times. Following the successful run with first round of larger
MCs, the CMLD designed an extended set (750 compounds, 6412 total conformers)
using the same scaffold and incorporating more substituents by expanding on the
sulfonyl chemistry seen in compounds 1, 6, 8, 14, 15 and 17. The results of the 750
compound set did not show many trends or repeated structures, especially for the C
side, with the exception of one structure, which is illustrated in Figure 3·8 A. For this
structure that appeared in the top hits multiple times the two substituents with the
5-6 bicyclic aromatic groups consistently aligned in similar locations and orientations
82
in the A side binding site, overlapping well with the hot spots.
3.3.2 Very Large Virtual Sets of Macrocycles
Based on the outcomes from the sets using the larger MC ring and substituents, the
CMLD explored further functionalization options for the ring with a third substitution
point and by including stereocenters (Fig. 3·9). A new set of possible substituents
(based on trends observed in previous results), another point of substitution, and the
incorporation of stereocenters, meant the next group of virtual MCs had the potential
to become very large (>100,000). However, the docking step was resource intensive
and slow, which was dramatically amplified for the larger MC scaffolds, requiring
almost a week per site (A and C side) for the sets containing >4000 compounds, even
when a set was run in pieces simultaneously and taking advantage of 32–48 processors
at a time. This long runtime is compared to sets of acyclic compounds or the small
bi-cyclic molecules with similar population size that had runtimes of 2–3 fewer days
per site. It became quickly apparent that, in order to obtain prioritized compounds
from the new sets of MCs, a preliminary coarse level refinement was required.
To address this problem we started a two part refinement of the virtual set, first
filtering by molecular properties followed by a gross assessment of pocket fit and
hot spot access. Because the large MC sets were being generated through simple
permutation of possible substituents (including groups with large non-polar rings) it
was understood that many of the compounds would be insoluble or too far outside
property ranges for good oral bioavailability. For the molecular properties filter, we
used the values from the guidelines established in the natural product MC study
(see Section 2.7), as they were specifically developed for MC design. The proper-
ties filtered on were molecular weight, polar surface area, number of hydrogen bond
acceptors and donors, and calculated octanol-water partition constant (cLogP) (see
Table 3.1 for ranges). Once the MC set was filtered using the guidelines for each
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Figure 3·8: Example of docking results for the larger MC scaffold and substituents
set. A top ranking structure is shown from the docking results of the A. A side cleft
and B. C side cleft of NEMO. Each compound is displayed with the mapping results
for that side (shown as lines). The structure for each of the example compounds is
to the right.
Figure 3·9: The first two scaffolds used for the design of 100K+ MC virtual sets.
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aforementioned property the CMLD generated five low energy conformers for each
remaining compound, to be used in the structure-based set refinement. The second
refinement step, based on gross compatibility of structure to binding site, evaluated
the ability of a compound to orient functional groups into the binding site hot spots.
This was performed using an in-house algorithm (developed by Dr. Dmitri Beglov)
that used the relative coordinates of the substituent ring centers to assess whether
the compound could satisfy the distance and orientation requirements necessary to
make use of the hot spots in the NBD clefts on NEMO. Once the substituents were
aligned in a way that satisfied the most hot spots, the compounds were evaluated for
how well they fit in the binding pocket. This evaluation was done by calculating the
distances between MC and protein atoms to determine the number of potential steric
clashes and their severity.
Table 3.1: Property ranges used to filter virtual sets of MCs.
Property Filtering Range Example Scaffold LS1
MW 500–1300 518–1245
TPSA 150–560 94–306
HBA 12–22 4–14
HBD 4–15 2–6
cLogP 0–4 0.7–12
This initial attempt at a method for refining very large sets was helpful to filter the
sets toward a more manageable size but has some drawbacks and is still in the early
stages of development. The majority of the refinement comes from the first step of
applying molecular property range cutoffs, which was expected and reasonable given
the size and polarity of some of the substituents; the limit of cLogP <5 alone tended
to scale down the sets by 80% or more. The number of virtual MCs were still in
the tens of thousands range though (before any alternate low energy conformers were
generated), and we needed a way to eliminate more compounds that were very unlikely
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to be viable binders before moving on to the resource intensive step of calculating
the energies of the complex (via docking). Given the constraints on MC flexibility
(see Section 1.1.2) the idea to screen compounds by their ability to reach all of the
relevant hot spots based solely on the low energy compound conformations is practical.
However, minimizing the computation time required the matching method to be
simple, so we started started by using the geometric center of the ring groups to
evaluate the distances used for determining occupancy. This approach arose mainly
from the fact that the IKKβ residues overlapping the NEMO hot spots contain six-
membered rings and the substituents of the first very large MC sets all contained a
six-membered ring group. Once this coarse level screening was performed for each
the A and C side clefts on NEMO, only those compounds remaining that appeared
on both sides were docked in the next step. Following docking the top 30 poses for
each side were passed along to the CMLD.
3.3.3 Early Outcomes
The overall NEMO project goal is to identify an inhibitor of the NEMO/IKKβ PPI,
but one salient objective on our path to a viable inhibitor was establishing a compu-
tational process for early stage lead generation. Although the computational methods
for designing and enriching MC compound libraries for inhibitor design are still un-
der development we were able to carry out early round refinement of the virtual sets,
resulting in sensible compounds for the NBD site. We also, and perhaps more im-
portantly, learned some things about docking and assessing MC binding that will be
considered for future work on MC inhibitors. Below I describe the outcomes from the
first rounds of 100K+ compound set refinement, followed by an overview of the whole
process used for library design, refinement, and prioritization, highlighting examples
of how the computational methods best served us.
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Results from the 100K+ Virtual MC Libraries
The first set of 100K+ virtual MC structures prepared by the CMLD was created using
the LS1 scaffold (Fig. 3·9). The LS1 virtual library contained ~350,000 compounds,
which was reduced to ~50,000 compounds following application of the molecular prop-
erties filters. A set of 147,209 total conformations was received from the CMLD to
be filtered by the course alignment screening program. The course alignment screen
retained 7631 conformations for the A side and 18,433 conformations from the C
side, with 6987 conformations common between them. Only those 6987 common
conformers moved on to the docking and hot spot correlation process (Sec. 3.3.1).
The structures of many of the top compounds from this set are illustrated in Figure
3·10. Compounds 19–26 were found in the A side cleft, with 19, 20, 24 and 25
represented multiple times. Compounds 27–34 were found in the C side cleft, with
only compound 28 represented multiple times.
While work was being done on the LS1 virtual set, problems with solubility of
some of the MC compounds became apparent during the proof of concept tests of the
inhibitor screens. Many of the early MCs synthesized for methodology testing were
based on the triage results for the two libraries created from the first large MC scaffold
(240 and 750 compound sets), and a lot of their substituent features were used in the
LS1 library design. Based on the clear trends seen for the R2 and R3 substituents
in the results of the LS1 top hits, the CMLD created a smaller, focused set with the
additional goal of reducing the cLogP of the compounds. Even though compounds
containing a substituent featuring the sulfonyl group were well represented in the top
LS1 hits, that group was not included in the focused LS1 follow up compound set.
This omission was due to the fact that the moiety appeared many times, but with
non-specific placement, raising concerns that its presence high in the rankings was an
artifact of how the docking software handled that chemistry. The focused LS1 MC
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Figure 3·11: The top ranking compounds from the focused library based on struc-
tural trends from top hits of LS1. Only one point on the scaffold was substituted.
set had 70 compounds (683 total conformers). The top ranking results of the docking
and hot spot correlation process can be seen in Figure 3·11.
Process Overview and Results
With the earliest virtual libraries of MCs we were looking for any preferences in
general substituent type or orientation as well as length and shape combinations of
scaffolds and substituents that provided the best fit for the cleft and the hot spots on
NEMO. An example of one of the pilot testing MC compounds is shown in Figure 3·6,
where the MC fits along the cleft in a reasonable configuration and easily accesses
the binding energy hot spots. Additionally, both substituents and part of the scaffold
overlap with the clustered EPS mapping results, Figure 3·6B, supporting its use
as a tool to inform further shape and orientation. The information from these early
docking results was used to inform later rounds of virtual set creation by looking both
for any specific groups that appeared in multiple high ranking structures, as well as
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any patterns of placement and alignment of other, more general structural features.
For example, the appearance and similar orientation of an indole group (Figure 3·6C)
from different structures meant it was kept and used in successive iterations. Similarly
if multiple aromatic bicyclic groups (e.g. indole, benzodioxolane, indene, napthalene,
quinoline, and quinazoline) were found in a similar location and orientation in the
site that could also be used to inform future designs.
We switched to the larger MC scaffolds in hopes of making better use of the
large area of the NBD cleft with more contacts, both through the larger ring itself
and the additional point of substitution it afforded. First, the small 240 and 750
compound libraries were created to evaluate the ability of the larger MCs to fit in
the binding site and orient the substituents so that they could reach the hot spots.
An example of the docking results from this large MC set can be seen in Figure 3·8,
where a top ranking docked compound from both the A side and C side cleft are
shown (3·8 A and B, respectively). The results of testing this pilot set of large MC
scaffolds demonstrated that these MCs were able to satisfactorily align along the NBD
cleft and adopt conformations that positioned substituents to easily access the hot
spots, which can be seen in the overlap with the mapping CSs in Figure 3·8. From
these results it was also observed that aromatic groups, especially the fused bicyclic
rings, showed up repeatedly in the high ranking docked poses, positioned towards the
bottom of the cleft.
With an appropriate site-fit confirmed for the large MC scaffolds and a process
for handling huge sets of compounds ready to test, we proceeded to analyze the
very large sets of MCs. The results and structures from refinement of the LS1 MC
set are discussed above. From the LS1 set results it was again clear that aromatic
groups positioned into the bottom of the cleft were preferred (see Fig. 3·12 A for
an example). Although there were some well represented structural features of the
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substituents found in both NEMO sites, there was no high-ranking MC compound
with a conformation orientation common to both the A and C side clefts. Using the
top 30 SL1 set compounds from each binding side the CMLD identified the R2 and
R3 substituents (Fig. 3·10) that appeared most frequently and in similar orientation
(Fig. 3·12 B). These substituents were then used to design a small, focused set of
virtual MC compounds. The resulting 70 compounds set gave rise to the interesting
outcome of a shared orientation across the A and C side clefts. Compounds 37 and
43, which only differ by a shift of the substituent attachment point, appeared in
a very similar conformation in sides A and C, respectively. In Figure 3·12 C the
parallel configuration of R2 and R3 can be seen towards the C terminus side of the
cleft, with an indole group on the opposite side of the cleft aligning near the same
NEMO residues on each side.
3.4 Future Prospects for NEMO Inhibitor Discovery
The early rounds of virtual library design and screening did not yield a viable inhibitor
for the IKK complex, but a lot was learned towards the development of the design
process and the protein complex remains a target of interest. One issue that arose
during our library refinement process is the deficit in current conformer generation
and docking software in handling MC structures. This portion of the process was
extremely slow and the limitations in what type of bonds Autodock Vina allowed
to move means that the largest MC structures were likely not fully explored. The
quasi-flexibility of a macrocyclic ring structure—where the bonds do not have free
rotation, but the structure also does not have the predictable rigidity of regular
aromatic compounds—makes it particularly challenging to model. Although we were
only looking for course-level refinement of our libraries in order to focus our synthetic
efforts, these deficiencies severely slowed down the process and limited the information
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we could obtain about any given compound set.
Another consideration for any MC design campaigns going forward arose from
the lessons of the natural product MC study (Chapter 2). Based on the results of
that study it is reasonable to surmise that the substituent-CS overlap utilized here,
in the virtual library screening, detrimentally impacted the results by removing MCs
that satisfied the hot spots with other parts of their structure. This is because the
results of the MC binding study showed that peripheral atoms of the MC scaffold—
and the ring atoms, to a lesser extent—also tend to participate in binding. Trying
to create large and diverse libraries while considering the binding potential of all the
atoms in the molecule would be quite difficult and time consuming. However, some
level of evaluation of likelihood for binding involvement could be incorporated into
the virtual assessment. Particularly, the triage of very large MC sets would most
likely benefit from a CS occupancy rating that took into account how many of any
MC atoms were close to the CS atoms. But, because substituent atoms tend to
occupy more of the highest ranked sub-sites, a weighted system could be applied so
those compounds with better overlap by substituents are indicated. A shift in the
algorithm to include all MC atoms in the assessment would also address the possible
bias to ring-containing substituents, which exists in the current state. Once a more
reliable method of in silico screening is achieved, work could also be implemented on
the NEMO sites recently discovered as potentially druggable, since these new sites are
also clefts that arise from the coiled coil topology meaning they may also be efficiently
accessed by a MC inhibitor.
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Chapter 4
Expansion of the FTMap Probe Library
The following is a short chapter describing my work on the creation and testing of an
expansion to the standard 16 probe set used by the FTMap program. This expanded
probe set was first used for the development and testing of the parameterization server,
created by Chi Ho Ngan, which allows for a user to include novel probes for protein
mapping with FTMap. The work outlined here covers the initial stages of library
expansion and application of the functional group clustering algorithm, created by
Dr. Brandon Zerbe, to extract information from the expanded set mapping results.
Efforts on this nascent expansion were paused early on because of concerns over
features of FTMap that may make identifying chemical specificity difficult, which
will be discussed below. These issues were outside the scope of this project and
would likely be a project all their own. The details of the probe set creation and
analysis are included here because of its use in generating a starting point for virtual
compound library design in the NEMO project (section 3.2.2), and its potential for
similar applications in the future.
4.1 Introduction
The ability to identify binding hot spots, both experimentally and virtually, has
become an important part of modern drug discovery campaigns. If, in addition to
location, information about chemical specificity or optimal conformation in those
binding sites could be determined, it would greatly improve the design process. Ideal
data about binding hot spots would include atomic property preferences like polarity
95
and hydrogen bonding, and spatial aspects like favorable size, shape, and orientation
of chemical groups. These features could be used for starting lead compound design
or filtering compound libraries, as well as for growing or optimizing known binders
into compounds with stronger affinity. Such a targeted approach is appealing for its
potential to shorten time spent in initial probes of novel targets and, then again, in
the optimization stage, while also reducing chemical and resource waste associated
with blind running of entire libraries. Furthermore, site specific insights could help
resolve some issues of protein-selectivity, which are always a consideration in drug
development campaigns (Knight and Shokat, 2005; Huggins et al., 2012; Capdeville
et al., 2002; Merino et al., 2010). Optimizing selective compounds based on differences
in chemical group preference among related proteins or similar binding sites can
limit off target toxicity and affect drug potency and lifetime (Copeland et al., 2006;
Liao, 2007; Kawasaki and Freire, 2011; Peters, 2013). Conversely, those interested
in harnessing promiscuity with specifically targeted polypharmacology could seek
preferred features common to the binding sites on a set of proteins (Hopkins et al.,
2006; Anighoro et al., 2014).
While the 16 probe, standard version of the FTMap algorithm has been shown to
reliably determine primary ligand binding sites and identify hot spots within those
sites (Brenke et al., 2009; Landon et al., 2009; Hall et al., 2012b), it is limited in the
amount of chemical and structural insight it can provide (Section 1.2). We decided to
augment the capabilities of FTMap in two ways: (1) user defined probes added to the
standard 16 when the job was submitted to the FTMap server; and (2) an expanded
set of predefined probes that could produce chemical specificity information about a
hot spot. Work on the FTMap extension of user-defined probes was carried out by
Chi Ho Ngan and is covered in a paper outlining the new server functionality and how
to run it (Ngan et al., 2012a). Included in that paper are some case studies and an
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overview of the type of results user-selected probes can provide. My work towards the
creation of an expanded fragment library, and a process for interpreting the results
from the large amount of data generated by those extra probes, is described in this
chapter. However, it should be noted that the two parts of the FTMap extension
are closely related. New probes were used for testing in the development of the user-
selection server, and the parameterization portion of the new server was employed to
generate usable probes for expanded set mapping.
4.2 Probe Set Creation and Functional Group Clustering
In order to improve chemical specificity of our fragment mapping, we needed to in-
crease both the overall size of the probe library and the complexity of its comprising
fragments. This was based on the hypothesis that repeated overlap of the same or
similar chemical groups from different and varied probes would indicate a preference
for that group in the hot spot. There were some important considerations we needed
to be aware of when expanding the probe library to maximize results while minimizing
computational pitfalls. (1) The total library size had to be large enough that probe
overlap was meaningful without becoming so large that a mapping run would be too
long or require too much processing power. (2) The complexity of individual probes
needed to be sufficient to provide diverse chemical moieties but not so complex as
to limit their ability to bind to the target. Additionally overly complex fragments
might be harder to incorporate onto a scaffold or grow into druglike molecules while
also being computationally more intensive as mapping probes. (3) The library should
be diverse, representing important functional groups and combinations, but without
bias towards certain types of protein binders.
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4.2.1 The Probe Set
Because we wanted the expanded probe set (EPS) to be representative of pharma-
cophores found in actual drugs, the initial library design was based on the fragments
and process used to create the Drug Fragment Set from Astex (Hartshorn et al., 2005).
The Astex set was built around the idea that a fairly comprehensive drug fragment
library could be created from well represented functional groups and scaffolds. The
EPS was generated using the simple ring systems and side chains identified by Astex,
which can be seen in Figure 4·1. The preferred side chains are those observed fre-
quently in drug molecules (Fig. 4·1 B) and the secondary side chains are lipophilic,
for indication of hydrophobic binding site interactions (Fig. 4·1 C).
Figure 4·1: Building blocks for the Astex Drug Fragment Set used in the creation
of the EPS. A. Simple carbocyclic and heterocyclic ring systems. B. Preferred side
chains, frequently observed in drug molecules. C. Secondary side chains, lipophilic
for hydrophobic interactions.
To create the preliminary probe set expansion the Astex preferred side chains and
secondary side chains were attached to a series of “space holder” groups, including
methyl, ethyl, isopropyl, t-butyl, furan and phenyl (Fig.4·2 and Fig. 4·3). The series
of space holder groups spanned a range of size and shape and were intended to present
varying levels of steric effects. The second segment of the preliminary expansion was
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the inclusion of the simple ring systems common to drug molecules (Fig. 4·4). The
new ring systems were included un-substituted in the EPS so that probe complexity
increased incrementally during initial testing. The rings could later be substituted
with the side chains at various positions, like the Fragment Drug Set virtual library
to achieve other types of chemistry. The full EPS used for the mapping discussed
below includes the new probes combined with the original 16, with only one copy of
redundant molecules retained, for a total probe count of 102. The t-butyl and methyl
groups from the Astex molecules were omitted from our side chain set because they
are represented in the space holders attached to other side chain-based probes and
would be over-represented if included again.
Because the 16 probes of the standard mapping set were simple molecules con-
taining no rotational degrees of freedom, the complex probes of the EPS were tested
for proper parameterization and conformational robustness before mapping was per-
formed. The EPS molecules were first created as SMILES strings which were then
used to generate 3D coordinates and multiple conformers, followed by generation of
parameter information (for grid search and CHARMM minimization). Sample sets of
200 conformers were visually inspected after interaction with a representative protein
field to ensure they could maintain realistic molecular conformations, e.g. no out-of-
plane distortions of aromatic rings. This work was done closely with Chi Ho Ngan,
and the results were used to inform the development of the parameterization server,
outlined in Ngan et al., 2012.
4.2.2 Functional Group Clustering
Once the initial creation and testing of the preliminary EPS was complete and sample
mapping runs were carried out, it was clear that the amount of data generated by the
larger probe set would be difficult to use in its raw state. The functional group cluster-
ing (FGC) algorithm was developed as a way to extract usable information from the
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Figure 4·2: EPS probes generated using the Astex preferred side chains.
100
Figure 4·3: EPS probes generated using the Astex secondary side chains.
Figure 4·4: EPS probes based on the Astex common drug ring systems.
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vast amount of raw probe data by looking for binding patterns among substructures
common to multiple probes. FGC first searches the probes of the mapping results for
predetermined functional groups (see Fig. 4·5), using the coordinates of the corre-
sponding probe atoms to write files with the functional group location information.
Once this process is complete for every probe and 3D placement data is recorded for
all substructures that were identified, functional group clusters are generated based
on population. Within each functional group type, all appearances are ranked by
number of other configurations with RMSD >4 A˚, the top ranked configuration and
its neighbors are removed, and the process is repeated until all functional groups are
assigned a cluster. To reduce bias, because some substructures simply appear in more
probes than others (e.g. benzene vs. amidine), the final ranking of the clusters are
normalized based on how many times a given functional group appears in the EPS.
4.3 Complications from FGC, Role of EPS in NEMO Project, and Future
Work
Although creation of EPS mapping was intended to provide details about chemical
specificity in binding sites, we were not able to devise a reliable way to extract that
information without requiring serious analytical intervention by the user. The FGC
was able to locate and display the target functional groups, but it was difficult to
discern any patterns only by looking at high ranking groups. This inability to provide
clear trends in functionality arises partially from the design of the probe set, selected
substructures, and FGC algorithm. Even with normalization, the presence of so many
aromatic ring structures in the probe set resulted in an abundance of similarly ranked
ring substructures that was likely an artifact. The population problem of the EPS was
compounded by the desire to obtain both general and specific functional group data,
resulting in many related groups appearing together in a site, sometimes making it
look like a stronger signal than it was in actuality. The other flaw in the FGC process
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Figure 4·5: The functional groups and substructures used for FGC.
FUR: furan, PYR: pyrrole, 5N2: five-membered aromatic with adjacent nitro-
gens, IMI: imidazole, 5N4: five-membered aromatic ring with four nitrogens,
A5R: arbitrary five-membered aromatic ring, A65: arbitrary fused 5-6 aromatic
ring system, BEN: benzene, PYI: pyridine, BON: pyrazine, PYD: pyrimidine,
TRI: 1,3,5-triazine, CHX: saturated arbitrary six-membered ring, A6R: arbitrary
aromatic six-membered ring, NAP: arbitrary fused 6-6 aromatic ring system,
PIP: piperidine, ALD: carbonyl, SLD: arbitrary atom double bonded to oxygen,
DMP: dimethylpropane, TFC: trifluoromethyl, SAM: sulfonamide, AM1: amine,
CO1: primary alcohol, CL1: alkyl chloride, FL1: alkyl fluoride, AMD: amide,
CXA: carboxylic acid, NXA: amidine, ANO: hydroxamic acid, MX1: methoxy,
COC: ether, NC2: nitrogen bonded to two carbons (e.g. imine)
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is the cluster ranking system, which is solely based on number of near neighbors and
lacks any indication of the energetic favorability of the contributing probe.
The more problematic factors that lead to ambiguous functional group clustering
results stemmed from intrinsic aspects of the FTMap algorithm and were, ultimately,
the reason the project was put on hold, as they are outside the scope of this work. One
such difficulty is the sheer number of consensus site (CS) members output by mapping
with the EPS. The parameters used for clustering individual probe types and then
generating the CSs have been optimized for the standard set of 16 probes and the re-
sults of EPS mapping could likely be improved by use of a set of parameters modified
for a larger number of input probes. However, two more possible limitations to provid-
ing chemical specificity were brought up by Brandon Zerbe during his development
of FGC, and pertain specifically to how FTMap functions as a mapping program.
Firstly, the FTMap algorithm identifies hot spot locations on proteins through aggre-
gation of varying probes, necessarily resulting in varying chemistry at the same site,
which makes discerning any chemical selectivity from top-ranking groups difficult.
The second issue he identified concerns the minimization step of FTMap, especially
its handling of hydrogen bond interactions between the probes and backbone engaged
hydrogens. Both of these complications arise from how FTMap was built as a hot spot
identification program and are likely detracting from the information an expanded
probe set could provide.
Even with the pitfalls uncovered during the development of EPS mapping and
FGC analysis, we were still able to extract usable information to apply to compound
library curation for use towards synthesis of an inhibitor. The steric restrictions of
the probes are still valid at binding spot sub-sites even when the chemical prefer-
ence is ambiguous; this applies to the size of a possible functional group as well as
its orientation out of the pocket. For the NEMO project (Chapter 3), this spatial
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arrangement information was used for both scaffold and substituent selection. The
scaffolds were selected based on their ability to reach highly populated FGC groups,
as oriented, and how well their points of substitution aligned to present functionality
in the right direction. For the substituents, even though the clustering results tended
not to indicate specific chemical moieties, trends of size and polarity were used to
triage an otherwise inordinate set of possible chemical groups. The results and stages
of design of these macrocycle libraries based on EPS and FGC are discussed in section
3.2.2.
Although the initial probe set expansion did not yield the desired details about
chemical specificity in binding sites, it still has the potential to be a useful tool for the
drug design process. Use of the initial probe expansion provided valid insights into
sterically suitable functional groups and their orientation and distances. However,
this information could be improved with modifications to the FTMap output, the
FGC algorithm, and the probe and substructure sets. Next steps for the project
should include the creation of a set of modified parameters for the basic FTMap
clustering algorithms, optimized for the increased number of probes. Work on the
FGC algorithm should address the ranking of functional groups, which are currently
based on population alone, possibly including some information on the energy ranking
of their constituent probes. Finally, new expanded probe sets should be created,
including a main set that is better balanced and subsets that could be used to focus
on particular types of binding sites. These improvements to EPS mapping will allow
for its continued use as an aid in compound library design.
Appendices
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Appendix A
Additional Tables and Figures
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Figure A·1: Ratio of non-polar/polar composition for the total MC and its buried
atoms for each MC in the test set.
108
Figure A·2: Binding geometries for large MCs in the test set.
109
Figure A·3: Binding geometries for small MCs in the test set. The black dashed
box indicates the four distinct MCs for which there are structures bound to hsp90.
The red dashed box indicates the four complexes that contain Radicicol.
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Table A.2: Size of the protein binding sites and polar ratio of those protein atoms. From
SASA calculations in Section 2.4.2
Protein (MC)
Buried % Non-polar/Polar
SASA (A˚2) Buried SASA
Large MCs
Actin (PTX-2) 436.76 62/38
Actin (RgA) 551.40 72/28
Actin (KabC) 593.75 75/25
FKBP (FK506) 370.36 61/39
FKBP (Rap) 391.74 60/40
Cyclophinin (CsA) 459.51 59/41
Cyclophilin (SfA) 543.01 65/35
Elastase (ScypA) 500.71 65/35
EF-TU (gea) 655.60 63/37
PP1a (nodR) 518.21 50/50
SPase (Aryl2) 372.94 69/31
Chitinase (rag) 454.47 64/36
Chitinase (rig) 405.55 55/45
Small MCs
Actin (lab) 352.43 57/43
Accoa Carboxylase (s1a) 382.87 69/31
hHSP90 (gdm) 393.94 59/41
hHSP90 (jzb) 364.87 81/19
yHSP90 (bc2) 396.99 65/35
yHSP90 (rdc) 257.15 72/28
PDK3 (rdc) 254.14 70/30
PhoQ (rdc) 263.70 75/25
Topoisomerase (rdc) 232.35 73/27
Large MCs 481± 89 63/37
Small MCs 322± 67 69/31
Test Set 416± 113 65/35
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Table A.3: Regional distibution and physicochemical composition of the MC atoms. For
results and discussion in Sections 2.3.2 and 2.3.2
Test Set Large MCs Small MCs
(n = 22) (n = 13) (n = 9)
Structural Composition
No. of Ring Atoms 22 ± 7 25 ± 7 17 ± 2
% of total HA 42 ± 10% 38 ± 8% 50 ± 6%
No. of Periph. Atoms 8.4 ± 4.5 9.9 ± 4.5 5.2 ± 2.4
% of total HA 15 ± 6% 15 ± 6% 15 ± 6%
No. of Subst. Atoms 24 ± 12 30 ± 10 12 ± 5
% of total HA 43 ± 14% 47 ± 13% 35 ± 11%
Average No. of Substs. 4.1 ± 1.9 4.7 ± 1.7 2.8 ± 1.7
Ring atoms/Periph. group 4.1 ± 1.9 4.7 ± 1.7 2.8 ± 1.7
Physicochemical Composition ( %Polar/%Non-Polar)
Total MC 28/72 ± 6% 29/71 ± 7% 26/74 ± 2%
Ring 15/85 ± 11% 19/81 ± 11% 7/93 ± 3%
Peripheral 60/40 ± 19% 62/38 ± 16% 57/43 ± 26%
Substituent 30/70 ± 11% 26/74 ± 10% 37/63 ± 11%
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Table A.4: Details of how the MC regions contribute to binding. For results and discussion
in Section 2.3.2
Test Set Large MCs Small MCs
(n = 22) (n = 13) (n = 9)
MC Regional Component of Total Buried SA
% ∆ASA due to Ring Atoms 21 ± 11% 15 ± 7% 29 ± 9%
% ∆ASA due to Periph. Atoms 24 ± 13% 22 ± 14% 26 ± 10%
% ∆ASA due to Substituents 55 ± 17% 62 ± 16% 46 ± 8%
% of Atoms in each Region that are Buried
Ring Atoms 35 ± 19% 25 ± 15% 51 ± 11%
Peripheral Atoms 81 ± 18% 72 ± 17% 94 ± 12%
Substituent Atoms 66 ± 21% 54 ± 17% 83 ± 13%
% of Buried Polar/Nonpolar atoms
Ring Atoms 7/93 ± 13% 10/90 ± 16% 3/97 ± 7%
Peripheral Atoms 60/40 ± 22% 59/41 ± 21% 60/40 ± 24%
Substituent Atoms 26/74 ± 14% 21/79 ± 16% 32/68 ± 10%
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Table A.7: Properties of 44 MCs that are approved drugs
Drug MW cLogP PSA (A˚2) HBA HBD NRB
Orally Bioavailable
Rifaximin 785.4 3.3 205.3 11 5 3
Amphotericin B 923.5 -2.3 324.1 17 12 3
Rifabutin 846.4 4.2 206.8 13 5 5
Rifampin 822.4 2.8 224.2 14 6 5
Sirolimus 913.6 7.5 195.4 12 3 6
Rifapentine 876.5 3.6 221.4 14 6 6
Tacrolimus 803.5 5.6 178.4 11 3 7
Azithromycin 748.5 2.4 182.5 13 5 7
Abamectin 874.5 5.8 170.1 13 3 8
Clarithromycin 747.5 3.2 184.1 13 4 8
Everolimus 957.6 7.4 204.7 13 3 9
Troleandomycin 813.5 4.3 185.4 12 0 12
Roxithromycin 836.5 3.0 218.1 16 5 13
Vancomycin 1447.4 -4.4 539.5 24 19 13
Erythromycin 861.5 3.4 227.5 14 4 14
Cyclosporin A 1201.8 3.6 278.8 12 5 15
Fidaxomicin 1056.4 8.6 269.5 15 7 15
Desmopressin 1068.4 -6.1 437.2 15 14 19
Average 921.4 3.1 247.4 14.0 6.1 9.3
Parenteral
Romidepsin 540.2 1.1 142.7 5 4 2
Ixabepilone 506.3 3.4 112.1 6 3 2
Natamycin 665.3 -1.7 235.4 13 7 3
Nystatin 925.5 -1.9 324.1 17 12 3
Metocurine 652.4 -1.8 55.4 4 0 4
Eribulin 729.4 2.3 148.0 12 2 4
Pimercolimus 809.4 6.8 158.1 10 2 6
Dalfopristin 690.3 1.6 177.6 9 2 7
Actinomycin D 1254.6 -0.1 355.5 16 5 8
Quinupristin 1021.5 2.2 232.4 12 4 10
Eptifibatide 831.3 -5.1 328.5 12 11 10
Capreomycin 668.3 -11.0 382.5 14 15 10
Viomycin 685.3 -11.0 395.3 15 16 10
Candicidin 1108.6 0.2 368.7 19 11 10
Temsirolimus 1029.6 7.1 242.0 14 4 11
Anidulafungin 1139.5 -1.5 377.4 17 14 14
Octreotide 1018.4 -1.4 335.5 12 13 17
Lanreotide 1095.5 -0.3 358.3 12 13 17
Oxytocin 1006.4 -5.0 401.2 13 12 17
Micafungin 1269.4 -6.3 513.0 22 16 18
Lypressin 1055.4 -6.8 428.8 14 13 19
Caspofungin 1092.6 -4.8 415.3 18 16 23
Polymyxin B 1202.7 -7.2 498.8 18 18 29
Telavancin 1753.6 -6.2 617.5 29 23 30
Bacitracin 1421.7 -7.2 541.0 20 17 31
Daptomycin 1619.7 -9.4 715.0 27 22 35
Average 992.1 -2.5 340.8 14.6 10.6 13.5
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